Page last updated: 2024-08-22

camptothecin and Neutropenia

camptothecin has been researched along with Neutropenia in 377 studies

Research

Studies (377)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	38 (10.08)	18.2507
2000's	185 (49.07)	29.6817
2010's	139 (36.87)	24.3611
2020's	15 (3.98)	2.80

Authors

Authors	Studies
Baek, G; Duong, A; Gralow, J; Jung, L	1
Hamada, M; Ichikawa, D; Imaya, M; Kawashima, N; Kojima, S; Miwata, S; Muramatsu, H; Narita, A; Narita, K; Nishikawa, E; Nishio, N; Takahashi, Y; Wakamatsu, M; Yamamori, A; Yoshida, T	1
Agarwal, N; Mathew Thomas, V; Swami, U; Tripathi, N	1
Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H	1
Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S	1
Lin, GH; Wang, BC; Xiao, BY	1
Aihara, R; Araki, K; Hatanaka, T; Hosaka, H; Hoshino, T; Hosouchi, Y; Ijima, M; Ishida, F; Ishii, N; Kakizaki, S; Kobatake, T; Kurihara, E; Naganuma, A; Shirabe, K; Suzuki, Y; Tamura, Y; Uraoka, T; Yasuoka, H; Yoshida, S	1
Kashihara, H; Nakao, T; Nishi, M; Shimada, M; Takasu, C; Tokunaga, T; Wada, Y; Yamashita, S; Yoshikawa, K; Yoshimoto, T	1
Ikushiro, S; Maruo, Y; Mimura, Y; Tagawa, K	1
Bianchini, G; Cortes, J; Henning, JW; Rugo, HS; Untch, M	1
Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S	1
Chang, JS; Chen, LT; Chiang, NJ; Hwang, DY; Li, YJ; Shan, YS; Shen, BN; Su, YY; Wang, YW	1
Boland, F; Daly, GR; Dowling, GP; Hennessy, BT; Hill, ADK; Keelan, S; Toomey, S	1
Chin, K; Kamiimabeppu, D; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Sato, T; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K	1
Ahn, S; Hwang, JH; Kim, HW; Kim, J; Kim, JW; Kim, YH; Lee, J; Lee, JC; Paik, KH	1
Sahota, S; Vahdat, LT	1
Bardia, A; Goldenberg, DM; Govindan, SV; Guarino, M; Isakoff, SJ; Maliakal, P; Mayer, IA; Messersmith, WA; Ocean, AJ; Picozzi, VJ; Sharkey, RM; Starodub, AN; Vahdat, LT; Wegener, WA	1
Chen, XM; Kong, SJ; Yin, JF; Zhang, HY; Zhang, J; Zhang, X	1
Crane, CH; Cuaron, JJ; Goodman, KA; Hajj, C; Lowery, MA; O'Reilly, EM; Park, JJ; Reyngold, M; Shi, W; Wu, AJ; Yu, KH; Zhang, Z	1
Aizawa, K; Furukawa, T; Kozakai, H; Mitsuboshi, S; Nagai, K; Yamada, H	1
Han, D; Li, S; Ren, X; Shang, W; Sun, L; Wang, G; Xu, L	1
Adam, R; Boige, V; Bouchahda, M; Carvalho, C; Desterke, C; Ducreux, M; Focan, C; Guimbaud, R; Hebbar, M; Innominato, P; Karaboué, A; Lemoine, A; Lévi, F; Milano, G; Saffroy, R; Smith, D; Taieb, J	1
Duan, Z; Pan, D; Peng, H; Wei, X; Wen, J	1
Alvarenga, EM; Araújo, AR; Brito, GAC; de Araújo, S; Iles, B; Júnior, JLP; Medeiros, JVR; Pacífico, DM; Sousa, DP; Sousa, NA; Souza, EP	1
Fukui, T; Igawa, S; Katagiri, M; Kubota, M; Kurahayashi, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ono, T; Ozawa, T; Sasaki, J; Shirasawa, M; Sone, H; Sugimoto, A; Sugita, K	1
Antoniotti, C; Aprile, G; Bordonaro, R; Ciuffreda, L; Di Bartolomeo, M; Di Costanzo, F; Fasola, G; Frassineti, GL; Iaffaioli, V; Leone, F; Maiello, E; Marchetti, P; Pastorino, A; Sobrero, A; Zaniboni, A; Zilocchi, C	1
Deng, B; Jia, L; Li, X; Li, Y; Lou, Y; Tan, H; Yu, L	1
Kawano, K; Matsukuma, K; Nasu, H; Nishio, S; Shimokawa, M; Tasaki, K; Terada, A; Tsuda, N; Ushijima, K; Yoshimitsu, T	1
Chuma, M; Fujino, H; Fukushima, K; Hamano, H; Horinouchi, Y; Ikeda, Y; Imanishi, M; Ishizawa, K; Izawa-Ishizawa, Y; Kirino, Y; Mitsui, M; Nakamura, T; Nimura, T; Okada, N; Takechi, K; Tamaki, T; Teraoka, K; Yanagawa, H; Zamami, Y	1
Chen, X; Lin, H; Shui, L; Shui, P; Sun, Q; Wu, YS	1
Cai, J; Li, N; Sui, Y; Sun, H; Wei, X; Xu, C; Zhang, G; Zheng, B; Zhuang, J	1
Abramson, VG; Bardia, A; Diamond, JR; Goldenberg, DM; Iannone, R; Isakoff, SJ; Kalinsky, K; Mayer, IA; Moroose, RL; O'Shaughnessy, J; Rugo, HS; Santin, AD; Shah, NC; Sharkey, RM; Sweidan, AM; Tolaney, SM; Vahdat, LT; Washkowitz, S; Wegener, WA	1
Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O	1
Aparicio, J; Bordonaro, R; Bury, D; Chau, I; Cicin, I; Di Bartolomeo, M; Drea, E; Fedyanin, MY; García-Alfonso, P; Heinemann, V; Karthaus, M; Kavan, P; Ko, YJ; Maiello, E; Martos, CF; Peeters, M; Picard, P; Riechelmann, RP; Sobrero, A; Srimuninnimit, V; Ter-Ovanesov, M; Yalcin, S	1
Fukuhara, T; Inoue, A; Ishimoto, O; Maemondo, M; Matsubara, N; Morikawa, N; Nukiwa, T; Sakakibara, T; Sugawara, S; Tanaka, M; Watanabe, K	1
Fukami, K; Hasegawa, J; Hirose, K; Kaneda, N; Kitamura, M; Maeda, Y; Maruo, E; Takada, H; Yamashita, K	1
Filip, S; Grim, J; Paulík, A	1
Gao, J; Jia, R; Li, Y; Lu, M; Shen, L; Zhou, J	1
Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U	1
Ge, FJ; Lin, L; Liu, ZY; Sharma, MR; Wang, Y; Xu, JM	1
Carlomagno, C; Cella, CA; De Placido, S; De Stefano, A; Matano, E; Moretto, R; Raimondo, L	1
Hong, YS; Jung, KH; Kim, SY; Kong, SY; Lim, HS; Park, SR; Park, YI; Seong, MW	1
Xu, JM	1
Ando, H; Fujita, Y; Hamamoto, Y; Hazama, S; Hinoda, Y; Inoue, Y; Kanekiyo, S; Kato, T; Kobayashi, M; Mishima, H; Nagata, N; Nozawa, H; Oba, K; Oka, M; Okayama, N; Okuyama, Y; Sakamoto, J; Takahashi, K; Takemoto, H; Tsunedomi, R	1
Akiyama, Y; Aoki, T; Fujii, M; Hagiwara, K; Hironaka, K; Kochi, M; Nakajima, T; Osuka, F; Takahashi, T; Takeuchi, M; Teranishi, F	1
Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA	1
Brutcher, E; Chen, Z; El-Rayes, BF; Hawk, N; Kauh, J; Kim, S; Kooby, DA; Landry, J; Mahaseth, H; Maithel, SK	1
Boku, N; Esaki, T; Fujitani, K; Hamamoto, Y; Hironaka, S; Hyodo, I; Morita, S; Moriwaki, T; Nagase, M; Nishina, T; Okamoto, I; Shimodaira, H; Sugimoto, N; Tokunaga, S; Tsuda, M; Tsumura, T; Ueda, S; Ura, T; Yamaguchi, K; Yasui, H	1
Chen, YJ; Chu, L; Fang, JM; Hu, F; Li, CY; Xu, Q; Zhang, X	1
Hamada, A; Harada, T; Kudoh, S; Maeno, K; Miyawaki, H; Moriyama, A; Nakagawa, K; Nakanishi, Y; Saeki, S; Shimokawa, M; Takayama, K	1
Doi, T; Fuse, N; Hamamoto, Y; Hatake, K; Iwasaki, J; Matsumoto, H; Mizunuma, N; Motomura, S; Ohtsu, A; Suenaga, M; Yamaguchi, T; Yamanaka, Y	1
Hwang, JH; Kim, DU; Kim, YT; Lee, MG; Lee, SH; Lee, SJ; Lee, YS; Ryu, JK; Woo, SM	1
An, GY; Gong, LL; Guo, CL; Han, FF; Li, GR; Liu, H; Liu, LH; Lv, YL; Yu, D; Zhu, J	1
Bertaut, A; Ghiringhelli, F; Ladoire, S; Lorgis, V; Rambach, L; Vincent, J	1
Cao, Y; Gong, J; Li, J; Li, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Wu, Y; Zhang, X; Zhou, J	1
Hasegawa, K; Ichikawa, R; Kato, R; Kawamura, K; Oe, S; Torii, Y; Udagawa, Y	1
Cao, J; Huang, XE; Liu, J; Lu, YY; Wang, L; Wu, XY; Xiang, J	1
Barni, S; Borgonovo, K; Coinu, A; Ghidini, A; Petrelli, F	1
Conte, M; Ellingrod, VL; King, AN; O'Malley, M; Ramnath, N	1
Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY	1
Bayraktar, S; Broome, P; de Queiroz Marques Junior, E; Leslie, M; Nowacki, M; Rocha-Lima, CM; Susnerwala, S; Weissman, C	1
Goto, K; Matsumoto, S; Morise, M; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K	1
Cruz, JE; Hermes-DeSantis, E; Jabbour, SK; Moss, RA; Nosher, JL; Saksena, R	1
Bennouna, J; Botbyl, J; de Labareyre, C; Delord, JP; Deslandres, M; Ruiz-Soto, R; Senellart, H; Suttle, AB; Wixon, C	1
Goto, A; Hamamoto, Y; Morita, S; Nakajima, T; Nakayama, N; Nishina, T; Sakamoto, J; Shimada, K; Ura, T; Yamada, Y; Yamaguchi, T; Yamazaki, K	1
Chen, HM; Chen, WS; Jiang, JK; Lan, YT; Lin, CC; Lin, JK; Teng, HW; Yang, SH	1
Alberts, SR; Berenberg, JL; Diasio, RB; Goldberg, RM; Lee, AM; Pavey, E; Sargent, DJ; Shi, Q; Sinicrope, FA	1
Cecchin, E; Chen, S; Court, MH; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Laverdiere, I; Lévesque, E; Toffoli, G; Tourancheau, A; Villeneuve, L	1
Crona, DJ; de Graan, AJ; Innocenti, F; Mathijssen, RH; Qiao, W; Ramirez, J; Ratain, MJ; Rosner, GL; van Schaik, RH	1
Chen, Y; Cheng, Y; Jiang, H; Ma, L; Yang, C; Zhu, J	1
Ando, Y; Fujita, K; Ichikawa, W; Minamimura, K; Miyauchi, H; Morita, S; Moriwaki, T; Nakamura, M; Ohashi, Y; Okutani, Y; Sadahiro, S; Sakata, Y; Shinozaki, K; Sugihara, M; Sugiyama, T; Takahashi, T; Takii, Y; Tanaka, C; Tsuji, A; Uehara, K	1
Buil-Bruna, N; Garrido, MJ; Mangas-Sanjuan, V; Soto, E; Trocóniz, IF	1
Azuma, Y; Hanashiro, K; Nakachi, A; Nishiki, T; Ota, M; Shimabuku, M; Shimabukuro, N; Shiroma, H; Teruya, T; Toritsuka, D	1
Akagi, Y; Emi, Y; Higashi, H; Ishikawa, H; Kusumoto, T; Maehara, Y; Matsuda, H; Miwa, K; Ogata, Y; Oki, E; Saeki, H; Samura, H; Sueyoshi, S; Tanaka, T; Tokunaga, S; Touyama, T	1
Inoue, A; Ishimoto, O; Maemondo, M; Nukiwa, T; Sugawara, S	1
Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M	1
Jiang, JL; Liu, Y; Ma, T; Xi, WQ; Yang, C; Ye, ZB; Zhang, J; Zhou, CF; Zhu, ZG	1
Cecchin, E; Chen, S; Couture, F; Guillemette, C; Innocenti, F; Jonker, D; Laverdière, I; Lévesque, E; Toffoli, G; Villeneuve, L	1
Ando, Y; Matsuoka, A	1
Bayever, E; Belanger, B; Blanc, JF; Bodoky, G; Braiteh, F; Chen, LT; Chiu, CF; Cunningham, D; Dean, A; Dhindsa, N; Hubner, RA; Jameson, G; Lee, KH; Li, CP; Macarulla, T; Moyo, V; Schwartsmann, G; Shan, YS; Siveke, JT; Von Hoff, DD; Wang-Gillam, A	1
Kusumi, T; Manabe, M; Miyata, Y; Mizunuma, N; Morita, Y; Taniguchi, F; Touyama, T	1
Akagi, Y; Baba, H; Emi, Y; Kawanaka, H; Kitazono, M; Maehara, Y; Maekawa, S; Miyamoto, Y; Murakami, H; Natsugoe, S; Ogata, Y; Oki, E; Saeki, H; Shimokawa, M; Tanioka, H; Tsuji, A	1
Atasilp, C; Chamnanphon, M; Chansriwong, P; Puangpetch, A; Reungwetwattana, T; Sirachainan, E; Sukasem, C; Wongwaisayawan, S	1
Liu, JY; Nie, YL; Wang, XF; Wei, LM; Yan, L; Zhang, LR	1
Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N	1
Ammari, S; Antoun, S; Bayar, MA; Chemama, S; Elias, D; Goéré, D; Lanoy, E; Raynard, B; Stoclin, A	1
Bateman, E; Bowen, JM; Campbell, JM; Keefe, DM; Peters, MD; Stephenson, MD	1
Caparello, C; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Petrini, I; Vasile, E; Vivaldi, C	1
Davies, A; Gandara, D; Huynh, M; Johl, J; Lara, P; Lau, D; Tanaka, M	1
Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B	1
Gelderblom, H; Guchelaar, HJ; Kweekel, D	1
Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T	1
Anthony, L	1
Eguchi, K; Isobe, H; Kunikane, H; Masuda, N; Ogura, T; Shibuya, M; Takahashi, T; Takeda, Y; Watanabe, K; Yamamoto, N; Yokoyama, A	1
Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M	1
Deeken, JF; Marshall, JL; Slack, R	1
Bai, Y; Chu, YP; Jin, ML; Li, J; Liu, DQ; Shen, L; Wang, YH; Xu, JM; Zhang, XD	1
Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J	1
Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P	1
Ilson, DH; Kelsen, DP; Kepler, S; O'Reilly, E; Radovich, D; Saltz, LB; Schrag, D; Schwartz, G; Tew, WP	1
Cao, W; Geng, M; Jiang, J; Jin, Y; Li, H; Lou, G; Ma, T; Xi, W; Yang, W	1
Ilson, DH; Kelsen, DP; Ku, GY; Maki, RG; O'Reilly, EM; Saltz, LB; Schrag, D	1
Gurney, H; Mathijssen, RH	1
Chen, P; Das, S; Dolan, ME; Innocenti, F; Kroetz, DL; Ramírez, J; Ratain, MJ; Relling, M; Rosner, GL; Schuetz, E	1
Carleton, JE; Chansky, K; Crowley, J; Dakhil, SR; Gandara, DR; Jett, J; Kuebler, JP; Langer, CJ; Lara, PN; Lenz, HJ; Natale, R; Redman, MW	1
Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E	1
Fukushima, M; Inui, K; Kanai, M; Katsura, T; Kobayashi, M; Matsumoto, S; Nishimura, T; Onoue, M; Shimizu, A; Terada, T; Teramukai, S; Yanagihara, K	1
Blinder, V; Gold, HT; Hall, MJ; Schackman, BR	1
Hoskins, JM; Innocenti, F; McLeod, HL; Ratain, MJ; Rosner, GL	1
Garcia-Bournissen, F; Ito, S; Kim, R; Nathan, PC; Sakaguchi, S; Schwarz, UI	1
Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N	1
Casey, DA; Chou, AJ; Merchant, MS; Merola, PR; Meyers, PA; Price, AP; Wexler, LH	1
Kang, JY; Kim, CH; Kim, HK; Kim, JS; Kim, JW; Kim, KH; Kim, SC; Kim, SJ; Kim, YK; Lee, SH; Moon, HS; Shim, BY; Song, JS; Yoon, HK	1
Bodnar, L; Stec, R; Szczylik, C	1
Han, SS; Kang, SB; Kim, HS; Kim, JW; Lee, HP; Park, NH; Seo, SS; Song, YS	1
Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xu, RH; Zhang, DS; Zhang, L	1
Jang, JS; Kim, BG; Kim, DK; Kim, HJ; Kim, MC; Kim, SG; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY	1
Hamaguchi, T; Kaniwa, N; Kim, SR; Kunitoh, H; Maekawa, K; Matsumura, Y; Minami, H; Nishimaki-Mogami, T; Ohe, Y; Ohtsu, A; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tamura, T; Yamada, Y; Yamamoto, N; Yoshida, T	1
Chelis, L; Christophyllakis, Ch; Georgoulias, V; Giassas, S; Kakolyris, S; Kalykaki, A; Kentepozidis, N; Kotsakis, A; Polyzos, A; Vamvakas, L; Vardakis, N; Xenidis, N	1
Cunningham, D; Yim, KL	1
Glisson, BS; Johnson, FM	1
Ahn, JS; Ahn, MJ; Kim, SW; Lee, DH; Lee, JC; Lee, JS; Na, II; Park, K; Ryoo, BY; Suh, C; Yang, SH	1
Chen, XX; Guo, GF; Hu, PL; Jiang, WQ; Liu, MZ; Qiu, HJ; Xia, LP; Zhang, B; Zhou, FF	1
Berglund, A; Berglund, M; Byström, P; Fredriksson, LA; Garmo, H; Glimelius, B; Kohnke, H; Sørbye, H; Wadelius, M	1
Furuya, K; Goto, T; Kato, M; Kikuchi, Y; Takano, M; Yoshikawa, T	1
Ahn, BJ; Choi, MK; Heo, JS; Kang, WK; Kim, S; Lee, J; Lim, HY; Noh, JH; Park, JO; Park, SH; Park, YS; Sohn, TS; Yim, DS	1
Bao, HY; Chen, J; Deng, J; Fang, WJ; Huang, S; Mou, HB; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC	1
Blumenschein, GR; Feng, L; Fossella, FV; Glisson, BS; Johnson, FM; Karp, DD; Peeples, BO; Stewart, DJ; Uyeki, J; William, WN	1
Dreiling, L; Gollard, R; Hecht, JR; Heim, W; Malik, I; Mo, M; Patel, R; Pillai, M; Swan, F	1
Fujita, K; Sparreboom, A	1
Beijnen, JH; Cendrós, JM; Friberg, LE; Huitema, AD; Karlsson, MO; Keizer, RJ; Obach, R; Peraire, C; Schellens, JH; Soto, E; Trocóniz, IF; Wanders, J	1
Fukuoka, M; Komiya, T; Kurata, T; Miyazaki, M; Nakagawa, K; Takeda, K; Tamura, K; Tsurutani, J; Yamamoto, N	1
Guo, C; Hu, ZY; Pei, Q; Yu, Q	1
Fushimi, K; Kumagai, K; Nakano, S; Yamamoto, N	1
Bodiagin, DA; Pokrovskiĭ, VS; Treshchalin, MI; Treshchalina, EM	1
Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW	1
de Jong, FA; Mathijssen, RH; Sleijfer, S; Sparreboom, A; van Daele, PL; van de Geijn, FE; van der Bol, JM; van Fessem, MA; van Schaik, RH; Verweij, J	1
Hatate, K; Hayakawa, K; Ihara, A; Koizumi, W; Naito, M; Nakamura, T; Okayasu, I; Onosato, W; Ozawa, H; Sato, T; Watanabe, M; Yamashita, K	1
Aguero, EG; Harper, JL; Kearney, PL; Reed, CE; Ruppert, BN; Sharma, AK; Sherman, CA; Shirai, K; Watkins, JM; Zauls, AJ	1
Fukuda, M; Kasai, T; Kinoshita, A; Kohno, S; Masuda, N; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K	1
Guo, GF; Jiang, WQ; Qiu, HJ; Wang, F; Xia, LP; Xu, RH; Zhang, B; Zhou, FF	1
Ge, FJ; Li, SS; Li, ZQ; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Zhao, CH	1
Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y	1
Barnett-Griness, O; Cohen, I; Gruber, SB; Kuten, A; Lejbkowicz, F; Rennert, G; Shulman, K	1
Saito, Y	1
Fujikawa, K; Hazama, S; Kato, T; Kimura, H; Kobayashi, M; Mishima, H; Nagata, N; Nozawa, H; Oba, K; Okuyama, Y; Sakamoto, J; Takahashi, K	1
Akiyama, Y; Ando, Y; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Mizuno, K; Saji, S; Sasaki, Y; Sunakawa, Y; Yamashita, K	1
Chon, HJ; Chung, HC; Jeung, HC; Kim, HS; Noh, SH; Park, HS; Rha, SY; Roh, JK; Shin, SJ	1
Akutsu, N; Fujii, H; Hamamoto, Y; Miyamoto, J; Nagase, M; Nishi, T; Warita, E; Yamanaka, Y	1
Blasco, H; Bourgoin, H; Le Guellec, C; Le Louarn, A; Lecomte, T; Pichereau, S	1
Bang, S; Chung, JB; Chung, MJ; Kim, YJ; Park, JY; Park, SW; Song, SY	1
Anderson, K; Burris, HA; Jones, S; Marier, JF; Pheng, L; Porubek, D; Trinh, MM; Warner, S	1
Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM	1
Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S	1
Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T	1
Ba, Y; Feng, FY; Guan, ZZ; He, J; Liang, J; Luo, RC; Qi, C; Qin, SK; Shen, L; Wang, D; Wang, JJ; Wang, LW; Xu, JM; Xu, RH; Yu, SY	1
Lee, PL; Sung, C; Tan, LL; Toh, DS	1
Hwang, JH; Kang, S; Lim, MC; Park, SY; Seo, SS; Yoo, HJ	1
Murayama, J; Okazaki, K; Saito, I; Watanabe, T	1
Huang, H; Li, H; Liu, JH	1
Daimon, T; Furuse, K; Kawahara, M; Mio, T; Okishio, K; Yanagihara, K; Yoshioka, H	1
Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S	1
Fujiwara, H; Harada, T; Itamochi, H; Kigawa, J; Machida, S; Oishi, T; Sato, S; Shimada, M; Suzuki, M; Takei, Y	1
Fujita, K; Ishida, H; Kato, Y; Miwa, K; Saji, S; Sasaki, T; Sasaki, Y; Sunakawa, Y; Yamashita, K	1
Ghang, HY; Han, JY; Hwang, JA; Kim, JY; Kim, SY; Lee, JS; Lee, YS; Shin, ES	1
Dias, MM; McKinnon, RA; Sorich, MJ	1
Brock, P; Brugières, L; Casanova, M; Child, M; Czauderna, P; de Camargo, B; Maibach, R; Morland, B; Pariente, D; Paris, C; Perilongo, G; Plaschkes, J; Roebuck, D; Ronghe, M; Zimmermann, A; Zsíros, J	1
Asao, T; Hosouchi, Y; Ishibashi, K; Ishida, H; Kigure, W; Kuwano, H; Ojima, H; Tsutsumi, S; Uchida, N; Yamauchi, S; Yashuda, N	1
Bradbury, J; Cave, J; Crabb, SJ; Johnson, PW; Muthuramalingam, SR; Nolan, L; Ottensmeier, C; Selman, D	1
Akyol, M; Bayoglu, IV; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Medeni, M; Somali, I; Tarhan, MO	1
Gao, F; Linehan, D; Lockhart, AC; Lubner, S; McWilliams, R; Menias, C; Peddi, PF; Picus, J; Sorscher, SM; Suresh, R; Tan, BR; Wang, J; Wang-Gillam, A	1
Alkis, N; Arpacı, E; Benekli, M; Berk, V; Bilici, A; Budakoglu, B; Buyukberber, S; Coskun, U; Dane, F; Demirci, U; Gumus, M; Inal, A; Isıkdogan, A; Kaya, AO; Ozkan, M; Yumuk, F	1
Ando, M; Gemma, A; Hino, M; Kobayashi, K; Kosaihira, S; Minegishi, Y; Miyanaga, A; Mizutani, H; Nomura, K; Noro, R; Okano, T; Seike, M; Yoshimura, A	1
Ansari, RH; Atkins, JN; Bogart, JA; Green, MR; Hodgson, LD; Kelley, MJ; Pang, H; Vokes, EE	1
Chaudhary, UB; Gudena, V; Keane, T; Verma, N	1
de la Fouchardière, C; Derbel, O; Méeus, P; Orlandini, F; Penet, AS; Pérol, M; Péron, J; Stella, M	1
Etoh, T; Hayashi, H; Inoue, K; Itoh, K; Kawamura, Y; Kikuyama, M; Kimura, M; Matsumura, T; Minami, S; Sonobe, M; Suzuki, T; Takagi, M; Tsuji, D; Utsuki, H; Yamazaki, T	1
Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M	1
Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA	1
Bélanger, AS; Cecchin, E; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Lévesque, E; Toffoli, G	1
Akagi, Y; Baba, H; Emi, Y; Kakeji, Y; Maehara, Y; Natsugoe, S; Nishimaki, T; Ogata, Y; Oki, E; Sadanaga, N; Saeki, H; Shirouzu, K; Tanaka, T; Tokunaga, S	1
Albertson, D; Blackstock, AW; Butler, JM; Howerton, R; Levine, E; Melin, SA; Patton, S; Pineau, B	1
Atagi, S; Furuse, K; Hosoe, S; Kawaguchi, T; Kawahara, M; Naka, N; Ogawara, M; Okishio, K; Takemoto, Y; Tsuchiyama, T; Ueno, K	1
Antonellini, A; Elfring, GL; Gillenwater, HH; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Sandler, AB; Socinski, MA	1
Chamberlain, MC	2
Adams, AL; Brady, D; Engstrom, PF; Gallo, JM; Kilpatrick, D; Lewis, NL; Litwin, S; Meropol, NJ; Scher, R; Szarka, CE; Weiner, LM	1
Gallagher, CJ; Shamash, J; Slater, S; Slevin, ML; Wilson, P	1
Bennouna, J; Ducreux, M; Hua, A; Lepille, D; Marre, A; Méry-Mignard, D; Mignot, L; Rougier, P	1
Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Kaufmann, SH; Miller, LL; Pitot, HC; Rubin, J; Sloan, JA	1
Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE	1
Borel, C; Caroli-Bosc, FX; Couteau, C; Desseigne, F; Hua, A; Jacob, JH; Kramar, A; Lefebvre, P; Merrouche, Y; Raoul, JL; Seitz, JF; Ychou, M	1
Douillard, JY; Eckardt, J; Scagliotti, GV	1
Rothenberg, ML	1
Agelaki, S; Androulakis, N; Aravantinos, G; Dimopoulos, MA; Foutzilas, G; Georgoulias, V; Giannakakis, T; Janninis, D; Kouroussis, C; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG	1
Eguchi, K; Goto, K; Hojo, F; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsumoto, T; Nishiwaki, Y; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Tamura, T; Yoshimura, K	1
Armand, JP; Boige, V; Fabbro, M; Faivre, S; Frenay, M; Germa, C; Raymond, E; Rixe, O; Rodier, JM; Sicard, E; Vassal, G; Vernillet, L	1
Hinkelbein, W; Mühr-Wilkenshoff, F; Ohnesorge, I; Riecken, EO; Scherübl, H; Wolf, KJ; Zeitz, M	1
Adachi, M; Ando, K; Hirose, T; Horichi, N; Hosaka, T; Ishida, H; Noguchi, H; Ogura, K; Ohmori, T	1
Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J	1
Colucci, P; Cristofanilli, M; DeJager, R; Duggal, A; Esteva, FJ; Hortobagyi, GN; Rivera, E; Royce, M; Valero, V	1
Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Galanis, E; Goetz, MP; Goldberg, RM; Pitot, H; Reid, JM; Rubin, J; Sloan, JA; Windebank, AJ	1
Auroux, J; Aziza, T; Braud, AC; Bugat, R; Buyse, M; Cherqui, D; Dupuis, O; Fagniez, PL; Ganem, G; Guimbaud, R; Haddad, E; Kobeiter, H; Piedbois, P; Piolot, A; Tayar, C; Valleur, P; Zelek, L	1
Doz, F; Frappaz, D; Germa, C; Imadalou, K; Mignard, D; O'Quigley, J; Pein, F; Risse, ML; Santos, A; Sicard, E; Vassal, G	1
Bourhis, JH; Carde, P; Fermé, C; Koscielny, S; Munck, JN; Ribrag, V; Rideller, K; Vantelon, JM	1
Arai, T; Goto, A; Hamaguchi, T; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y; Yasui, H	1
Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J	1
Hochster, H; Mandeli, J; Muggia, FM; Plimack, ER; Runowicz, CD; Sorich, J; Speyer, J; Wadler, S; Wallach, RC; Wright, J	1
Ariyoshi, Y; Fukuoka, M; Hoso, T; Katakami, N; Kawahara, M; Kudoh, S; Matsui, K; Nakagawa, K; Nakano, T; Negoro, SI; Saito, H; Senba, H; Sugiura, T; Takada, Y; Yamamoto, N	1
Bafaloukos, D; Bamias, A; Economopulos, T; Fountzilas, G; Janinis, J; Kalofonos, HP; Kouvatseas, G; Papakostas, P; Skarlos, D; Stavropoulos, M; Timotheadou, E	1
McLeod, HL; Watters, JW	1
Chen, PX; Das, S; Innocenti, F; Iyer, L; Janisch, L; Karrison, T; Kocherginsky, M; Ramírez, J; Ratain, MJ; Rudin, CM; Undevia, SD; Vokes, EE	1
Ando, M; Gemma, A; Hibino, S; Kobayashi, K; Kudoh, S; Kurimoto, F; Mizutani, H; Moriyama, G; Nara, M; Okano, T; Seike, M; Shibuya, M; Yoshimura, A	1
Abbruzzese, JL; Bogaard, KR; Hoff, PM; Lassere, Y; Pazdur, R; Saad, ED; Wolff, R	1
Bissett, D; Cassidy, J; de Bono, JS; Fraier, D; Magnè, ML; Main, M; Muirhead, F; Pellizzoni, C; Porro, MG; Robson, L; Speed, W; Spinelli, R; Twelves, C	1
Fujiwara, K; Hisamoto, A; Hosokawa, S; Hotta, K; Kiura, K; Kozuki, T; Kuyama, S; Satoh, K; Tabata, M; Tanimoto, M; Ueoka, H	1
Gemba, K; Harita, S; Kamei, H; Kiura, K; Nogami, N; Segawa, Y; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T	1
Bereder, JM; Bernardini, D; Cals, L; Deplanque, G; Favre, R; François, E; Herait, P; Juin, P; Laadem, A; Merad, L; Rixe, O	1
Holcombe, RF; Kong, KM; Wimmer, D	1
Chin, K; Ishihara, S; Maruyama, M; Nakajima, T; Ohta, K; Ohyama, S; Takahashi, T; Yamao, T	1
Agelidou, A; Ardavanis, A; Boukovinas, I; Georgoulias, V; Kouroussis, C; Palamidas, P; Polyzos, A; Stavrinidis, E; Syrigos, K; Toubis, M; Tselepatiotis, E; Veslemes, M; Vlachonikolis, I	1
Hütter, G; Keilholz, U; Krebs, P; Schmittel, A; Schulze, K; Thiel, E	1
Goto, K; Kakinuma, R; Kodama, T; Kubota, K; Kunitoh, H; Matsui, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Nokihara, H; Ohe, Y; Ohmatsu, H; Saijo, N; Sekine, I; Shinkai, T; Sugiura, T; Tamura, T; Yamamoto, N; Yoshida, K	1
Carlo, WF; Fong, Y; Gonen, M; Hummer, AJ; Jarnagin, W; Kemeny, N; Schwartz, L; Sullivan, D	1
Fukuda, M; Inoue, Y; Kasai, T; Kinoshita, A; Kohno, S; Kuba, M; Nagashima, S; Nakamura, Y; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsurutani, J	1
Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E	1
Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y	1
Cheung, YB; Chowbay, B; Leong, SS; Poon, D; Tan, EH	1
André, T; de Gramont, A; Gamelin, E; Garcia, ML; Kalla, S; Lenaers, G; Louvet, C; Méry-Mignard, D; Saavedra, A	1
Gourgou-Bourgade, S; Kramar, A; Ychou, M	1
Govindan, R; McLeod, H; Read, W	1
Campbell, C; Harvey, H; Kerr, S; Legore, K; Lipton, A; Witters, L	1
Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H	1
Assadourian, S; de Jong, FA; de Jonge, MJ; Dumez, H; Eskens, FA; Lefebvre, P; Sanderink, GJ; Selleslach, J; Soepenberg, O; Sparreboom, A; Ter Steeg, J; Thomas, J; van Oosterom, AT; van Schaik, RH; Verweij, J	1
Chin, K; Hatake, K; Mizunuma, N; Ohkochi, N; Ota, K; Shinozaki, E; Tanabe, M	1
Aparicio, J; Balcells, M; Bosch, C; Busquier, I; Campos, JM; Galán, A; Garcerá, S; Llorca, C; López-Tendero, P; Maestu, I; Vicent, JM	1
Alfonso, R; Carcas, A; Cortés-Funes, H; Díaz-Rubio, E; Frías, J; Grávalos, C; Guerra, P; Paz-Ares, L; Pronk, L; Sastre, J	1
Berghorn, E; Centeno, B; Daud, A; Deconti, RC; Derderian, J; Hausheer, F; Liu, Z; Munster, P; Sullivan, D; Sullivan, P; Urbas, P; Valkov, N	1
Kosmas, Ch; Malamos, NA; Pergantas, N; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Tsavdaridis, D; Xynotroulas, J	1
Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML	1
Chung, G; Mehra, R; Murren, J; Psyrri, A; Smith, B	1
Fioravanti, S; Grem, JL; Guo, X; Harold, N; Hopkins, JL; Leguizamo, JP; Leonard, GD; Lin, P; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Wright, MA	1
Agelidou, A; Androulakis, N; Boukovinas, I; Chandrinos, V; Georgoulias, V; Ignatiadis, M; Kentepozidis, N; Mylonaki, E; Vossos, A; Zachariadis, E; Ziotopoulos, P	1
Beale, P; Clarke, S; Liddell, S; Noney, L; Rivory, LP; Tobin, PJ	1
Ahn, JS; Chang, HM; Kang, WK; Kang, YK; Kim, HK; Kim, SR; Kim, TW; Lee, KH; Park, JO; Ryoo, BY; Zang, DY	1
Han, JY; Kim, EA; Kim, HY; Lee, DH; Lee, HG; Lee, JS; Lee, SY; Park, CG; Yoon, SM	1
Chan, AT; Ho, WM; King, A; Koh, J; Lai, P; Leow, CK; Lim, R; Ma, B; Mok, T; Wong, YY; Yeo, W	1
Andersen, N; Brandt, D; Davies, MJ; Murren, JR; Nadkarni, R; Parisot, N; Pizzorno, G; Psyrri, D; Rose, M; Rosenfield, AT; Zelterman, D	1
Cendrós, JM; Garrido, MJ; Obach, R; Peraire, C; Principe, P; Segura, C; Trocòniz, IF	1
Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L	1
Lokich, J	1
Berry, S; Billingsley, K; Croitoru, M; Gallinger, S; Krishnamurthi, S; Mackay, HJ; Pond, GR; Siu, LL; Smith, A; Swanson, PE; Yeung, R	1
Dimou, E; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Xynotroulas, JP	1
Battaglia, C; Colucci, G; Di Bisceglie, M; Gebbia, N; Gebbia, V; Giuliani, F; Maiello, E; Molica, S; Vinciarelli, G	1
Berg, K; Hammond, LA; Izbicka, E; Kuhn, J; Mita, MM; Ochoa, L; Patnaik, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Yeh, IT	1
Arcamone, G; Bertolini, P; Bisogno, G; Carli, M; Paolucci, P; Prete, A; Provenzi, M; Riccardi, R; Ruggiero, A; Surico, G	1
Ballas, MS; Dennis, PA	1
Bisonni, R; Leon, A; Lippe, P; Lombardo, M; Marcucci, F; Massacesi, C; Mattioli, R; Pilone, A; Rocchi, MB; Terrazzino, S	1
Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E	1
Kawahara, M	1
Masubuchi, N	1
Kalofonos, HP; Karabelis, A; Kosmas, C; Koutras, A; Makatsoris, T; Mylonakis, N; Stathopoulos, GP; Syrigos, K; Tsakonas, G; Tsavaris, N	1
McLeod, HL	1
Akita, H; Ishida, H; Kabuto, T; Nakaguchi, K; Watanabe, Y	1
Cisar, LA; Compton, LD; Duncan, BA; Elfring, GL; Goel, R; Goldberg, RM; Gruia, G; Hammond, LA; Kuhn, JG; McGovren, JP; Miller, LL; Pirotta, N; Rothenberg, ML; Schaaf, LJ; Sharma, A; Tipping, SJ; Yin, D	1
Iwamoto, S; Yoshioka, K	1
Kudou, T; Munakata, M; Sakata, Y; Shitara, K	1
Eguchi, T; Shirao, K	1
Goto, A	1
Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S	1
Kawamura, S; Okumura, S; Shimada, E; Sumi, Y; Tei, M; Yamagishi, D	1
Hahn, KK; Kolesar, JM; Wolff, JJ	1
Higa, GM	1
Ando, M; Eguchi, K; Fukuoka, M; Ichinose, Y; Kudoh, S; Matsui, K; Nakagawa, K; Negoro, S; Saito, H; Tada, T; Takada, M; Takada, Y; Tamura, K	1
Booth, BP; Gobburu, JV; Ibrahim, A; Innocenti, F; Johnson, JR; Mehta, M; Rahman, A; Ramchandani, RP; Ratain, MJ; Wang, Y	1
Baker, S; Bulgaru, A; Camacho, F; Chaudhary, I; Desai, K; Einstein, M; Goel, S; Goldberg, G; Gollamudi, R; Karri, S; Kaubisch, A; Mani, S	1
Ikami, I; Ishiguro, A; Kasai, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Sakuraba, H; Shitara, K	1
Adachi, M; Ando, K; Hirose, T; Hosaka, T; Ishida, H; Kusumoto, S; Nakashima, M; Ohmori, T; Shirai, T; Sugiyama, T	1
Honda, K; Kondo, H; Ohura, K; Sumiyoshi, T; Takahari, D; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N	1
Chu, DT; Han, FC; Liu, DQ; Xiu, QY; Zhang, XR; Zhu, YZ	1
Cheng, J; Li, J; Wu, CP; Wu, Q; Xu, LG; Xu, N; Zhang, W; Zhao, ZY	1
Harita, S; Hotta, K; Kiura, K; Kuyama, S; Okimoto, N; Segawa, Y; Shinkai, T; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T	1
Berenguer, R; Ferrandini, S; Garberi, J; Politi, P; Trini, E; Valsecchi, M	1
Yoneda, S	1
Han, JY; Kim, HT; Lee, DH; Lee, JE; Lee, JS; Lee, SY; Lim, HS; Park, YH; Shin, ES; Yoo, YK	1
Fujiwara, Y; Fukui, T; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Simmyo, Y; Tamura, T; Yamada, K; Yamamoto, N	1
de Jong, FA; de Jonge, MJ; Friberg, LE; Loos, WJ; Mathijssen, RH; Planting, AS; Sparreboom, A; van der Bol, JM; van Schaik, RH; Verweij, J	1
Chowbay, B; Goh, BC; Jada, SR; Lee, SC; Lim, R; Shu, X; Wong, CI; Zhou, Q	1
Arena, MG; Di Lauro, L; Foggi, P; Lopez, M; Nunziata, C; Sperduti, I	1
Fakih, MG; Ross, ME; Starostik, P	1
He, YJ; Jiang, WQ; Li, YH; Luo, HY; Shi, YX; Wang, F; Xu, RH; Zhang, L	1
Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T	1
Cai, RG; Chen, SS; Chu, DT; Wu, F; Zhang, HG	1
Heo, DS; Kim, JS; Kim, NK; Kim, SW; Lee, DH; Lee, JH; Lee, JS; Lee, SJ; Park, K; Ryoo, BY; Suh, C	1
Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N	1
Alvarez Silva, M; Fernandes, D; Hangai, M; Lemos-Senna, E; Loch-Neckel, G; Nemen, D; Puhl, AC; Santos Silva, MC; Stimamiglio, MA	1
Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K	1
Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Kawara, K; Kodama, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W	1
Hahm, JR; Hwang, IG; Hwang, YS; Jeong, YY; Kang, JH; Kang, MH; Kim, HC; Kim, HG; Kim, SH; Lee, GW; Lee, JD; Lee, JS	1
de Jong, FA; Mathijssen, RH; Sparreboom, A; van der Bol, JM; van Gelder, T; Verweij, J; Wiemer, EA	1
Jung, SS; Kim, JO; Kim, SY; Lee, JE; Park, HS	1
Carcereny, E; Casado, E; Fernández-Llamazares, J; Font, A; Gallego, R; Guix, M; Manzano, JL; Maurel, J; Ramirez, JL; Rosell, R; Salazar, R; Tabernero, J; Taron, M	1
Biason, P; Masier, S; Toffoli, G	1
Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS	1
Bonneterre, J	1
Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL	1
Brewster, L; Green, MR; Hargis, JB; Hollis, DR; Lilenbaum, RC; Miller, AA; O'Brien, SM; Ratain, MJ; Rosner, GL; Schilsky, RL	1
Beijnen, JH; Davies, BE; Koier, I; Maes, RA; Rodenhuis, S; Rosing, H; ten Bokkel Huinink, WW; van Warmerdam, LJ	1
Bugat, R; Chabot, GG; Culine, S; de Forni, M; Extra, JM; Gouyette, A; Madelaine, I; Marty, ME; Mathieu-Boué, A	1
Chen, TL; Donehower, RC; Ettinger, DS; Grochow, LB; Lubejko, BG; Rock, MK; Rowinsky, EK; Sartorius, SE	1
Ishida, T; Izuo, M; Nakao, I; Ogawa, M; Oguro, M; Ohkawa, T; Taguchi, T; Tominaga, T; Yoshida, M; Yoshida, Y	1
Chou, TC; Conti, JA; Gonzalez, C; Huang, Y; Kemeny, NE; Pulliam, S; Saltz, LB; Sun, M; Tong, WP	1
Allegra, C; Arbuck, S; Chen, A; Corse, W; Dahut, W; Grem, J; Grollman, F; Hamilton, JM; Harold, N; Liang, M; Lieberman, R; Nakashima, H; Sorensen, M; Takimoto, C	1
Green, MR; Lilenbaum, RC; Lynch, TJ; Miller, AA; Ratain, MJ; Rosner, GL; Schilsky, RL	1
Armand, JP; Couteau, C; Goncalves, E; Terret, C; Yakendji, K	1
DeVore, R; Glick, J; Hutson, P; Johnson, D; Kim, K; Schiller, JH; Stewart, J	1
Hasuo, Y; Imaishi, K; Kataoka, A; Komai, K; Nishida, T; Ookura, N; Sugiyama, T; Ushijima, K; Yakushiji, M	1
Bleiberg, H; Cvitkovic, E	1
Alvarez, RD; Armstrong, DK; Barker, SD; Bookman, MA; Fleming, GF; Horowitz, IR; McGuire, WP; O'Reilly, S; Ozols, RF; Rowinsky, EK; Schilder, RJ; Walczak, JR	1
Adenis, A; Becouarn, Y; Bonneterre, J; Brunet, P; Bugat, R; Burki, F; Conroy, T; Culine, S; Douillard, JY; Extra, JM; Ganem, G; Herait, P; Mahjoubi, M; Marty, M; Merrouche, Y; Mousseau, M; Namer, M; Negrier, S; Rougier, P; Seitz, JF; Suc, E; Ychou, M	1
Boku, N; Fujii, T; Fukuda, H; Kondo, H; Muro, K; Oda, Y; Ohtsu, A; Oka, M; Ono, H; Saito, D; Shimada, Y; Shirao, K; Watanabe, Y; Yamao, T; Yokoyama, T; Yoshida, S	1
Beijnen, JH; Dennis, MJ; Grochow, LB; van Warmerdam, LJ	1
Janik, JE; Saltz, L	1
Robert, F; Soong, SJ; Wheeler, RH	1
Creemers, GJ; de Boer-Dennert, M; DePee, S; Gerrits, CJ; Harteveld, M; Planting, AS; Pritchard, JF; Schellens, JH; Verweij, J; Wissel, P	1
Berkery, R; Harrison, J; Kelsen, DP; Kemeny, NE; Saltz, LB; Tong, W	1
Bailey, H; Durivage, HJ; Gelder, M; Irvin, WP; Potkul, RK; Price, FV; Rosenbluth, R	1
Edwards, CL; Ende, K; Freedman, RS; Giovanella, BC; Kavanagh, JJ; Kudelka, AP; Natelson, EA; Stehlin, JS; Verschraegen, CF	1
Baker, SD; Burke, TG; Burris, HA; DePee, S; Eckardt, JR; Eckhardt, SG; Fields, S; Kuhn, JG; Kunka, R; Littlefield, D; Rodriguez, G; Rothenberg, ML; Rowinsky, EK; Smith, L; Thurman, A; Von Hoff, DD; Warner, DL; White, L; Wissel, P	1
Berg, D	1
Bartel, S; Bharti, A; Hurwitz, S; Levy, S; Lynch, C; Rosowsky, A; Rubin, E; Toppmeyer, D; Trites, D; Wood, V	1
Cersosimo, RJ	1
Armand, JP; Boige, V; Raymond, E	1
Armand, JP; Couteau, C	1
Cox, JV; DeVore, RF; Elfring, GL; Geyer, CE; Hainsworth, JD; Macdonald, JS; Miller, LL; Mohrland, JS; Pazdur, R; Rivkin, SE; Rothenberg, ML; Sandbach, J; Von Hoff, DD; Wolf, DL	1
Candalh, E; Kramar, A; Lebecq, A	1
Chauvergne, J; Chevallier, B; Dieras, V; Fargeot, P; Fumoleau, P; Krakowski, Y; Lentz, MA; Lhommé, C; Matthieu-Boué, A; Mignard, D; Misset, JL; Rebattu, P; Roche, H; Van Glabbeke, M; Vennin, P	1
Beijnen, JH; Herben, VM; Hillebrand, MJ; Lieverst, J; Porro, MG; Schellens, JH; Schoemaker, NE; Schot, M; ten Bokkel Huinink, WW; van Gijn, R	1
Dallaire, BK; de Jonge, MJ; Gelderblom, AH; Loos, WJ; Planting, AS; Punt, CJ; Sparreboom, A; van Beurden, V; van der Burg, ME; van Maanen, LW; Verweij, J; Wagener, DJ	1
Armand, JP; Bexon, A; Bonnay, M; Ducreux, M; Mahjoubi, M; Méry-Mignard, D; Rougier, P; Seitz, JF; Ychou, M	1
de Boer-Dennert, MM; de Jonge, MJ; Jacques, C; Planting, AS; Sparreboom, A; ter Steeg, J; van der Burg, ME; Verweij, J	1
Fujiyoshi, K; Hasuo, Y; Hirai, N; Kamura, T; Kumagai, S; Nishida, T; Nishio, S; Oota, S; Sugiyama, T; Tomioka, Y	1
Furman, WL; Hanna, SK; Houghton, PJ; Ma, MK; Radomski, KM; Santana, VM; Smith, AK; Stewart, CF; Zamboni, WC	1
Jelic, S; Nikolic-Tomasevic, Z; Popov, I; Radosavljevic, D	1
Halme, M; Jekunen, A; Kivisaari, L; Knuuttila, A; Linnainmaa, K; Mali, P; Mattson, K; Ollikainen, T	1
Fukuoka, M; Kudoh, S; Masuda, N; Nakagawa, K; Negoro, S; Niitani, H; Saka, H; Sugiura, T; Takada, M	1
Awad, L; Bleiberg, H; Bugat, R; Culine, S; Droz, JP; Freyer, G; Herait, P; Marty, M; Mignard, D; Rougier, P; Trillet-Lenoir, V	1
Coyle, J; De Jager, RL; Drengler, R; Eckhardt, SG; Geyer, CE; Hammond, LA; Johnson, TR; Rizzo, J; Rowinsky, EK; Schwartz, G; Smetzer, L; Tolcher, A; Von Hoff, DD	1
Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB	1
Mayer, RJ	1
Armand, JP; Boige, V; Ducreux, M; Faivre, S; Gatineau, M; Meely, K; Mekhaldi, S; Pautier, P; Raymond, E; Rixe, O	1
Agelaki, S; Georgoulias, V; Kakolyris, S; Kourousis, CH; Malliotakis, P; Mavroudis, D; Sarra, E; Souglakos, J	1
Cvitkovic, E; Di Palma, M; Goldwasser, F; Gross-Goupil, M; Marceau-Suissa, J; Misset, JL; Tigaud, JM; Wasserman, E; Yovine, A	1
Kelsen, DP; Kemeny, NE; O'Reilly, EM; Raeburn, L; Saltz, LB; Sanz-Altamira, PM; Schwartz, GK; Steger, CM; Stuart, KE	1
Elfring, GL; Hanover, CK; Israel, VK; Locker, PK; Miller, LL; Natale, RB; Pirotta, N; Sandler, AB; Socinski, MA	1
Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Erlichman, C; Goldberg, RM; Kaufmann, SH; Okuno, SH; Pitot, HC; Rubin, J; Sloan, J	1
Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H	1
Arbuck, S; Argiris, A; Cooper, DL; DiStasio, S; Foss, FM; Heald, P; Kuzel, T; Murren, JR	1
Fujii, H; Igarashi, T; Itoh, K; Minami, H; Oguma, T; Sasaki, Y; Tamanoi, K	1
Algazy, K; Giantonio, B; Haller, DG; Hardy, C; Kluijtmans, LA; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Whitehead, AS	1
Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H	1
Coyle, J; De Jager, RL; Ducharme, MP; Hollywood, E; Ilson, D; Kelsen, D; Kemeny, N; Kleban, S; O'Reilly, E; Saltz, LB; Schwartz, GK; Sharma, S	1
Ando, M; Ando, Y; Hasegawa, Y; Ikeda, T; Minami, H; Saka, H; Sakai, S; Sato, M; Sekido, Y; Shimokata, K; Watanabe, A; Yamamoto, M	1
Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML	1
Chin, K; Goto, M; Matsumura, Y; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yamao, T	1
Ajani, JA; Baker, J; Charnsangavej, C; Feig, BW; Ho, L; Mansfield, PF; Pisters, PW	1
Bos, AM; Cameron, T; de Jonge, MJ; de Vries, EG; Groen, HJ; Hamilton, M; Kehrer, DF; Loos, WJ; Sparreboom, A; Verweij, J	1
Bedikian, AY; Ellerhorst, JA; Eton, O; Papadopoulos, NE; Plager, C; Smith, TM	1
Delioukina, ML; Hecht, JR; Parson, M; Prager, D; Rosen, LS; Rosen, P	1
Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N	1
Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hammett, E; Moore, JO; Payne, N; Rizzieri, DA; Rosner, GL	1
de Bruijn, P; Loos, WJ; Mathijssen, RH; Nooter, K; Sparreboom, A; Verweij, J	1
Ettinger, DS; Forastiere, AA; Grochow, LB; Hendricks, CB; Hurowitz, LA; Kaufmann, SH; Lubejko, BG; McGuire, WP; Rowinsky, EK; Sartorius, SE	1

Reviews

43 review(s) available for camptothecin and Neutropenia

Article	Year
Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. Expert review of anticancer therapy, 2022, Volume: 22, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Diarrhea; Humans; Immunoconjugates; Irinotecan; Neutropenia; Urinary Bladder Neoplasms	2022
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO open, 2022, Volume: 7, Issue:4 Topics: Alopecia; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Fatigue; Female; Humans; Immunoconjugates; Lung Diseases, Interstitial; Nausea; Neutropenia; Trastuzumab; Ventricular Dysfunction, Left; Vomiting	2022
Efficacy and Safety of Trastuzumab Deruxtecan in Breast Cancer: A Systematic Review and Meta-Analysis. Clinical breast cancer, 2023, Volume: 23, Issue:8 Topics: Anemia; Breast Neoplasms; Camptothecin; Female; Humans; Neutropenia; Receptor, ErbB-2; Trastuzumab	2023
Sacituzumab govitecan: an antibody-drug conjugate. Expert opinion on biological therapy, 2017, Volume: 17, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Humans; Immunoconjugates; Irinotecan; Neoplasms; Neutropenia; Urologic Neoplasms	2017
UGT1A16 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis. Cancer chemotherapy and pharmacology, 2017, Volume: 80, Issue:1* Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Dose-Response Relationship, Drug; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Risk Factors	2017
Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis. European journal of cancer care, 2017, Volume: 26, Issue:6 Topics: Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Diarrhea; Etoposide; Fatigue; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Nausea; Neoplasm Staging; Neutropenia; Odds Ratio; Proportional Hazards Models; Small Cell Lung Carcinoma; Thrombocytopenia; Vomiting	2017
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 48, Issue:5 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Databases, Factual; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Neutropenia; Organoplatinum Compounds; Proportional Hazards Models; Risk; Survival Rate; Treatment Outcome	2018
Predictors of irinotecan toxicity and efficacy in treatment of metastatic colorectal cancer. Acta medica (Hradec Kralove), 2012, Volume: 55, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Humans; Irinotecan; Neutropenia; Pharmacogenetics	2012
[Relationship between UGT1A and irinotecan-related toxicity]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Single Nucleotide	2013
The association of UGT1A16 and UGT1A128 with irinotecan-induced neutropenia in Asians: a meta-analysis. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 2014, Volume: 19, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Risk	2014
Associations between UGT1A16 or UGT1A16/28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:4* Topics: Alleles; Amino Acid Sequence; Asian People; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Molecular Sequence Data; Neoplasms; Neutropenia; Polymorphism, Single Nucleotide; Topoisomerase I Inhibitors	2014
A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer. Anti-cancer drugs, 2014, Volume: 25, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardiotoxicity; Colorectal Neoplasms; Diarrhea; Humans; Irinotecan; Liver; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes	2014
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:7 Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Docetaxel; Enzyme Induction; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Nicotine; Paclitaxel; Polycyclic Aromatic Hydrocarbons; Quinazolines; Smoking; Taxoids	2014
[UGT1A1 Genotyping for Proper Use of Irinotecan]. Rinsho byori. The Japanese journal of clinical pathology, 2015, Volume: 63, Issue:7 Topics: Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic	2015
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. The Cochrane database of systematic reviews, 2016, Feb-12, Volume: 2 Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Nausea; Neutropenia; Quality of Life; Randomized Controlled Trials as Topic	2016
Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. The pharmacogenomics journal, 2017, Volume: 17, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genetic Predisposition to Disease; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Meta-Analysis as Topic; Neutropenia; Odds Ratio; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Predictive Value of Tests; Reproducibility of Results; Risk Assessment; Risk Factors; Systematic Reviews as Topic; Treatment Outcome	2017
Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. Nature clinical practice. Oncology, 2008, Volume: 5, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis; Randomized Controlled Trials as Topic; Risk Factors	2008
Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer treatment reviews, 2008, Volume: 34, Issue:7 Topics: Adult; Age Distribution; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacogenetics; Pharmacology, Clinical; Risk Assessment; Sex Distribution; Survival Analysis; Treatment Outcome	2008
Irinotecan toxicity. Current opinion in supportive and palliative care, 2007, Volume: 1, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; ErbB Receptors; Genetic Predisposition to Disease; Humans; Irinotecan; Neutropenia	2007
Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question. Cancer, 2008, Oct-01, Volume: 113, Issue:7 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Irinotecan; Metabolic Networks and Pathways; Models, Biological; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Risk Assessment	2008
Pharmacogenetics of irinotecan disposition and toxicity: a review. Current clinical pharmacology, 2010, Volume: 5, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic	2010
Dose-dependent association between UGT1A128 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Aug-01, Volume: 16, Issue:15* Topics: Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic	2010
[Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2011, Volume: 131, Issue:2 Topics: Antineoplastic Agents; Camptothecin; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Polymorphism, Genetic	2011
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-10, Volume: 29, Issue:20 Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Logistic Models; Middle Aged; Multivariate Analysis; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Proportional Hazards Models; Stomatitis; Survival Analysis; Treatment Outcome	2011
Impact of the UGT1A128 allele on response to irinotecan: a systematic review and meta-analysis. Pharmacogenomics, 2012, Volume: 13, Issue:8* Topics: Alleles; Antineoplastic Agents, Phytogenic; Biomarkers, Pharmacological; Camptothecin; Diarrhea; Genetic Association Studies; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Neoplasms; Neutropenia	2012
Challenging the platinum combinations in the chemotherapy of NSCLC. Lung cancer (Amsterdam, Netherlands), 2002, Volume: 38 Suppl 4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids	2002
Current status of capecitabine in the treatment of colorectal cancer. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:12 Suppl N Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prodrugs; Risk Factors; Stomatitis; Survival; Treatment Outcome	2002
Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations. Expert opinion on drug safety, 2006, Volume: 5, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Diarrhea; Dose-Response Relationship, Drug; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Patient Compliance; Quality of Life	2006
Individualizing cancer chemotherapy. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:4 Topics: Camptothecin; Enzyme Inhibitors; Genetic Testing; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Neutropenia; Toxicogenetics	2006
[S-1 for gastric cancer-S-1 monotherapy and its progress]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1 Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Leukopenia; Neutropenia; Oxonic Acid; Quality of Life; Stomach Neoplasms; Stomatitis; Tegafur	2006
[S-1 as a single agent for colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1 Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leukopenia; Neutropenia; Oxonic Acid; Survival Rate; Tegafur	2006
[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1 Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neutropenia; Oxonic Acid; Remission Induction; Survival Rate; Tegafur	2006
Pharmacogenetics and irinotecan therapy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006, Nov-15, Volume: 63, Issue:22 Topics: Antineoplastic Agents; Bilirubin; Biomarkers; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Drug Labeling; Genetic Predisposition to Disease; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Polymorphism, Genetic; Practice Guidelines as Topic; Risk Assessment	2006
UGT1A128 and other UGT1A polymorphisms as determinants of irinotecan toxicity. Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:2* Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Gene Frequency; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Neoplasm Metastasis; Neoplasms; Neutropenia; Polymorphism, Genetic	2008
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan]. Bulletin du cancer, 1995, Volume: 82, Issue:8 Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Topotecan; Vomiting	1995
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials]. Bulletin du cancer, 1996, Volume: 83, Issue:1 Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors	1996
Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A Suppl 3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Humans; Irinotecan; Middle Aged; Neutropenia	1996
An overview of the clinical pharmacology of topotecan. Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Camptothecin; Chemical Phenomena; Chemistry, Physical; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Half-Life; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Lactones; Metabolic Clearance Rate; Models, Chemical; Neutropenia; Solubility; Topoisomerase I Inhibitors; Topotecan; Water	1997
Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor? Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5 Topics: Antineoplastic Agents; Bone Marrow; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan	1997
Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer. Oncology nursing forum, 1998, Volume: 25, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Gastrointestinal Diseases; Humans; Irinotecan; Neutropenia; Patient Care Planning; Topoisomerase I Inhibitors	1998
Irinotecan: a new antineoplastic agent for the management of colorectal cancer. The Annals of pharmacotherapy, 1998, Volume: 32, Issue:12 Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia	1998
[Irinotecan: various administration schedules, study of drug combinations, phase I experience]. Bulletin du cancer, 1998, Volume: Spec No Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Hepatic Artery; Humans; Inactivation, Metabolic; Injections, Intra-Arterial; Injections, Intravenous; Irinotecan; Neoplasm Proteins; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Topoisomerase I Inhibitors	1998
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas]. Bulletin du cancer, 1998, Volume: Spec No Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome	1998

Trials

221 trial(s) available for camptothecin and Neutropenia

Article	Year
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer. Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neutropenia; Rectal Neoplasms; Retrospective Studies	2023
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer, 2017, Oct-01, Volume: 123, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Adhesion Molecules; Female; Glucuronosyltransferase; Half-Life; Humans; Immunoconjugates; Immunoglobulin G; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Response Evaluation Criteria in Solid Tumors; Time Factors	2017
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). British journal of cancer, 2017, Sep-26, Volume: 117, Issue:7 Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arylamine N-Acetyltransferase; ATP Binding Cassette Transporter, Subfamily B; Camptothecin; Catecholamine Plasma Membrane Transport Proteins; Cetuximab; Colorectal Neoplasms; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Glucuronosyltransferase; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Survival Rate; Treatment Outcome; Vitamin K Epoxide Reductases	2017
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. Clinical colorectal cancer, 2018, Volume: 17, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cohort Studies; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Hypertension; Italy; Leucovorin; Male; Middle Aged; Neutropenia; Progression-Free Survival; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Stomatitis; Surveys and Questionnaires	2018
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A128 and UGT1A16 polymorphisms. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2017, Volume: 37, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Polymorphism, Genetic; Treatment Outcome; Vomiting; Young Adult	2017
A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis. Gynecologic oncology, 2018, Volume: 150, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma; Diarrhea; Disease-Free Survival; DNA-Binding Proteins; Endometrial Neoplasms; Endonucleases; Female; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Survival Rate; Thrombocytopenia; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein	2018
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. The New England journal of medicine, 2019, 02-21, Volume: 380, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Adhesion Molecules; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Immunoconjugates; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Progression-Free Survival; Survival Rate; Triple Negative Breast Neoplasms	2019
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). Clinical colorectal cancer, 2019, Volume: 18, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Patient Reported Outcome Measures; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Severity of Illness Index; Treatment Outcome; Young Adult	2019
Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703. Respiratory investigation, 2013, Volume: 51, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Endpoint Determination; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Salvage Therapy; Survival Rate; Treatment Outcome	2013
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. Breast cancer (Tokyo, Japan), 2015, Volume: 22, Issue:4 Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Polymorphism, Genetic; Pyridines; Survival Analysis; Tegafur; Treatment Outcome	2015
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:5 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptothecin; Cohort Studies; Colorectal Neoplasms; Cytochrome P-450 CYP2A6; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Half-Life; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Polymorphism, Genetic; Stomach Neoplasms; Survival Analysis; Tegafur	2013
UGT1A16, 1A73, and 1A922 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer science, 2013, Volume: 104, Issue:12* Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gene Frequency; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; UDP-Glucuronosyltransferase 1A9	2013
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Incidence; Japan; Leucovorin; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Stomatitis; Survival Analysis	2013
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:2 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome	2014
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Dec-10, Volume: 31, Issue:35 Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Paclitaxel; Platinum; Prospective Studies; Stomach Neoplasms; Treatment Failure; Treatment Outcome	2013
A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer. Japanese journal of clinical oncology, 2014, Volume: 44, Issue:2 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Febrile Neutropenia; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Protective Agents; Treatment Outcome	2014
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. Journal of clinical pharmacology, 2014, Volume: 54, Issue:5 Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Interactions; Female; Fluorouracil; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome	2014
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Republic of Korea; Salvage Therapy; Tegafur; Treatment Outcome; Uracil	2014
A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Gastrins; Humans; Infusions, Intravenous; Injections, Intramuscular; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Vomiting	2014
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. Investigational new drugs, 2015, Volume: 33, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Sulfonamides; Topoisomerase I Inhibitors; Treatment Outcome	2015
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study). The oncologist, 2014, Volume: 19, Issue:11 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Treatment Outcome; Young Adult	2014
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). Journal of the National Cancer Institute, 2014, Volume: 106, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Diarrhea; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genetic Predisposition to Disease; Humans; Leucovorin; Logistic Models; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Polymorphism, Single Nucleotide; Prospective Studies; Severity of Illness Index; Thrombocytopenia; Valine; Vomiting	2014
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). International journal of clinical oncology, 2016, Volume: 21, Issue:1 Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fatigue; Female; Fluorouracil; Humans; Hypertension; Leucovorin; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Survival Rate; Thrombosis; Vomiting	2016
Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study. Respiratory investigation, 2015, Volume: 53, Issue:4 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Diarrhea; Feasibility Studies; Febrile Neutropenia; Female; Humans; Hypokalemia; Hyponatremia; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Small Cell Lung Carcinoma; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting	2015
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet (London, England), 2016, Feb-06, Volume: 387, Issue:10018 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Treatment Outcome; Vomiting	2016
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). International journal of clinical oncology, 2016, Volume: 21, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Tegafur; Treatment Outcome	2016
Population-based phase I trial of irinotecan and epirubicin. American journal of clinical oncology, 2008, Volume: 31, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Drug Synergism; Epirubicin; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Topoisomerase I Inhibitors	2008
UGT1A128 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. British journal of cancer, 2008, Jul-22, Volume: 99, Issue:2* Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Fever; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin	2008
Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clinical pharmacology and therapeutics, 2009, Volume: 85, Issue:2 Topics: Aged; Aged, 80 and over; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia; Polymorphism, Genetic; Treatment Outcome	2009
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Spain; Survival Analysis; Time Factors; Treatment Outcome	2009
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Rectal Neoplasms; Remission Induction; Survival Rate; Vomiting; Young Adult	2008
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Time Factors; Treatment Outcome	2009
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Quinazolines	2009
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. Investigational new drugs, 2009, Volume: 27, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel	2009
Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer. Anti-cancer drugs, 2009, Volume: 20, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult	2009
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. Cancer investigation, 2009, Volume: 27, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Digestive System Neoplasms; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Time Factors; Treatment Outcome	2009
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, May-20, Volume: 27, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Diarrhea; Etoposide; Female; Glucuronosyltransferase; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pharmacogenetics; Polymorphism, Single Nucleotide; Risk Factors; Small Cell Lung Carcinoma	2009
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC cancer, 2009, Apr-22, Volume: 9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Survival Analysis; Treatment Outcome	2009
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatric blood & cancer, 2009, Volume: 53, Issue:6 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Colitis; Dacarbazine; Diarrhea; Female; Humans; Irinotecan; Male; Neutropenia; Pneumonia; Recurrence; Remission Induction; Retrospective Studies; Sarcoma, Ewing; Temozolomide; Thrombocytopenia; Young Adult	2009
A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease Progression; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Small Cell Lung Carcinoma; Survival Analysis; Topoisomerase I Inhibitors	2010
Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer. Annals of the New York Academy of Sciences, 2009, Volume: 1171 Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Epithelial Cells; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Treatment Outcome	2009
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer]. Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Rectal Neoplasms; Remission Induction; Salvage Therapy; Survival Rate; Vomiting; Young Adult	2009
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer. American journal of clinical oncology, 2010, Volume: 33, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Treatment Outcome	2010
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cisplatin; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Neoplasms; Neutropenia; Organic Anion Transporters; Polymorphism, Single Nucleotide	2010
Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 68, Issue:3 Topics: Aged; Camptothecin; Cisplatin; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy, Adjuvant; Small Cell Lung Carcinoma	2010
Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer. Cancer, 2010, Jan-01, Volume: 116, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma	2010
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. The pharmacogenomics journal, 2011, Volume: 11, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neutropenia; Retrospective Studies; Survival Rate; Thymidylate Synthase; Treatment Outcome	2011
Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:1 Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fever; Follow-Up Studies; Gastrectomy; Humans; Infusions, Parenteral; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Peritoneal Dialysis, Continuous Ambulatory; Peritoneal Neoplasms; Stomach Neoplasms	2011
Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pyrimidines; Survival; Vomiting; Young Adult	2011
Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer, 2010, May-15, Volume: 116, Issue:10 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Small Cell Lung Carcinoma	2010
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clinical colorectal cancer, 2010, Volume: 9, Issue:2 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Disease Progression; Double-Blind Method; Female; Fever; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Odds Ratio; Organoplatinum Compounds; Polyethylene Glycols; Recombinant Proteins; Risk Factors; Young Adult	2010
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Investigational new drugs, 2011, Volume: 29, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Discovery; Female; Humans; Leukocyte Count; Male; Middle Aged; Models, Biological; Neutropenia; Predictive Value of Tests; Sulfonamides; Treatment Outcome	2011
A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904). Japanese journal of clinical oncology, 2010, Volume: 40, Issue:10 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome	2010
A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. International journal of radiation oncology, biology, physics, 2011, Mar-01, Volume: 79, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Japan; Leukopenia; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Oxonic Acid; Rectal Neoplasms; Tegafur	2011
Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A16 and UGT1A127 with severe neutropenia. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Polymorphism, Genetic; Risk Factors; Survival Rate; Treatment Outcome	2011
[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Colonic Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Rate; Young Adult	2010
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Genetic Predisposition to Disease; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; Severity of Illness Index; Topoisomerase I Inhibitors; Treatment Outcome	2011
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Oxonic Acid; Patient Selection; Salvage Therapy; Serum Albumin; Stomach Neoplasms; Survival; Tegafur; Treatment Outcome	2011
Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer. Chemotherapy, 2011, Volume: 57, Issue:3 Topics: Adult; Aged; Alanine Transaminase; Anemia; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Positron-Emission Tomography; Survival Rate; Thrombocytopenia; Tomography, X-Ray Computed	2011
Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors. Journal of pharmaceutical sciences, 2011, Volume: 100, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Chemistry, Pharmaceutical; Emulsions; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Succinates; Technology, Pharmaceutical; Vitamin E	2011
Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). Oncology, 2011, Volume: 80, Issue:1-2 Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome	2011
Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. International journal of clinical oncology, 2012, Volume: 17, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia	2012
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chinese journal of cancer, 2011, Volume: 30, Issue:10 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies; Survival Rate; Young Adult	2011
Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer. Anti-cancer drugs, 2012, Volume: 23, Issue:3 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Thrombocytopenia; Treatment Outcome	2012
A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02. Japanese journal of clinical oncology, 2012, Volume: 42, Issue:5 Topics: Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Survival Analysis; Treatment Outcome	2012
Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Combinations; Female; Humans; Hypertension; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Severity of Illness Index; Tegafur; Treatment Outcome	2012
Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies. Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:1 Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Genetic Variation; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds	2012
Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL). European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:18 Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Camptothecin; Child; Child, Preschool; Combined Modality Therapy; Diarrhea; Female; Hepatectomy; Hepatoblastoma; Humans; Infant; Irinotecan; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Salvage Therapy; Treatment Outcome	2012
Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study. Oncology, 2012, Volume: 83, Issue:3 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Survival Rate; Treatment Outcome	2012
A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer. Chemotherapy, 2012, Volume: 58, Issue:4 Topics: Adult; Antineoplastic Agents; Area Under Curve; Camptothecin; Carboplatin; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Sepsis; Small Cell Lung Carcinoma; Thrombosis	2012
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP : Journal of the pancreas, 2012, Sep-10, Volume: 13, Issue:5 Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome	2012
Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer. Anticancer research, 2012, Volume: 32, Issue:10 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Severity of Illness Index; Small Cell Lung Carcinoma; Thrombocytopenia; Treatment Outcome	2012
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemoradiotherapy; Cisplatin; Confidence Intervals; Dehydration; Disease-Free Survival; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Small Cell Lung Carcinoma	2013
A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer. American journal of clinical oncology, 2014, Volume: 37, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Urinary Bladder Neoplasms	2014
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:6 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia; Quality of Life; Time Factors; Treatment Outcome; Venous Thrombosis	2013
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-01, Volume: 31, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome	2013
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. The Journal of pharmacology and experimental therapeutics, 2013, Volume: 345, Issue:1 Topics: 3' Untranslated Regions; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Genetic Markers; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies; Severity of Illness Index	2013
Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701). Oncology, 2013, Volume: 84, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; In Vitro Techniques; Leucovorin; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Treatment Outcome; Vomiting	2013
Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:5 Suppl 5 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Irinotecan; Neutropenia; Pancreatic Neoplasms	2002
Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2002, Volume: 37, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival; Thrombocytopenia	2002
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma. Cancer, 2002, Oct-01, Volume: 95, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Paclitaxel; Survival Analysis; Vomiting	2002
Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas. Journal of neuro-oncology, 2002, Volume: 59, Issue:2 Topics: Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Gastrointestinal Diseases; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Polypharmacy; Prospective Studies; Salvage Therapy	2002
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed. Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Quinazolines; Thiophenes	2002
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Survival; Treatment Outcome	2002
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Neutropenia	2002
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. Oncology, 2002, Volume: 63, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Survival Rate; Treatment Outcome; Vomiting	2002
High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Enzyme Inhibitors; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Prodrugs; Rectal Neoplasms; Remission Induction; Safety; Topoisomerase I Inhibitors; Treatment Outcome	2002
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:3 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pain; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome	2003
Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507. British journal of cancer, 2003, Mar-24, Volume: 88, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Thrombocytopenia	2003
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Treatment Outcome; Vomiting	2003
A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. International journal of colorectal disease, 2003, Volume: 18, Issue:4 Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Survival Analysis	2003
Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2003, Volume: 40, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome	2003
A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome	2003
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer, 2003, Sep-01, Volume: 98, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Treatment Outcome	2003
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Oct-15, Volume: 21, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases	2003
Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neutropenia	2003
A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Oct-15, Volume: 21, Issue:20 Topics: Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Child, Preschool; Drug Administration Schedule; Humans; Infant; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Neoplasms; Neutropenia	2003
Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas. Leukemia & lymphoma, 2003, Volume: 44, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Recurrence; Salvage Therapy; Survival Analysis; Topoisomerase I Inhibitors; Treatment Outcome	2003
Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. International journal of clinical oncology, 2003, Volume: 8, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Fatigue; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur	2003
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. Methods and findings in experimental and clinical pharmacology, 2003, Volume: 25, Issue:8 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Spain; Treatment Outcome; Vomiting	2003
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome	2004
Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803). British journal of cancer, 2004, Jan-12, Volume: 90, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Survival Analysis; Taxoids; Vomiting	2004
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma. Cancer investigation, 2003, Volume: 21, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Survival Analysis	2003
Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2004, Volume: 44, Issue:1 Topics: Aged; Antacids; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Magnesium Oxide; Male; Middle Aged; Neutropenia; Sodium Bicarbonate; Survival Analysis; Treatment Outcome; Water	2004
Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. Investigational new drugs, 2004, Volume: 22, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome	2004
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). British journal of cancer, 2004, Jul-05, Volume: 91, Issue:1 Topics: Acrylamides; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Sepsis; Thrombocytopenia	2004
A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2004, Volume: 45, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel	2004
Phase I study of docetaxel and irinotecan in patients with advanced non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2004, Volume: 45, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Docetaxel; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids	2004
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Humans; Infusion Pumps; Irinotecan; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Time Factors; Treatment Outcome	2004
Combined topoisomerase I inhibition for the treatment of metastatic colon cancer. Anti-cancer drugs, 2004, Volume: 15, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Patient Selection; Remission Induction; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome; Vomiting	2004
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. British journal of cancer, 2004, Aug-02, Volume: 91, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Taxoids	2004
Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer. Onkologie, 2004, Volume: 27, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neutropenia; Radiography; Thrombocytopenia; Treatment Outcome	2004
Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. British journal of cancer, 2004, Aug-16, Volume: 91, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome	2004
Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer. Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:6 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Thrombocytopenia	2004
Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. Medical oncology (Northwood, London, England), 2004, Volume: 21, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neutropenia; Prospective Studies; Safety; Time Factors	2004
Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. International journal of clinical oncology, 2004, Volume: 9, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome	2004
Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. Cancer, 2005, Feb-01, Volume: 103, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Neutropenia; Quality of Life; Salvage Therapy; Survival Analysis; Treatment Outcome	2005
A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients. Bulletin du cancer, 2004, Volume: 91, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Quinazolines; Rectal Neoplasms	2004
Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Treatment Outcome	2004
Gemcitabine/Irinotecan/celecoxib in pancreatic cancer. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome	2004
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-01, Volume: 11, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gene Frequency; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Polymorphism, Genetic; Prognosis; Prospective Studies; Treatment Outcome; UDP-Glucuronosyltransferase 1A9	2005
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-15, Volume: 11, Issue:4 Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Capsules; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; Dietary Fats; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting	2005
First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study. Oncology, 2005, Volume: 68, Issue:1 Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Irinotecan; Male; Middle Aged; Neutropenia; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome; Vomiting	2005
A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours. Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:5 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Female; Fluorouracil; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia	2005
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Apr-15, Volume: 11, Issue:8 Topics: Adult; Aged; Anemia; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Fatigue; Female; HL-60 Cells; Humans; Male; Melanoma; Middle Aged; Nausea; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting	2005
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:5 Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neutropenia; Taxoids	2005
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. British journal of cancer, 2005, May-23, Volume: 92, Issue:10 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dehydration; Diarrhea; Drug Interactions; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome	2005
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jun-01, Volume: 11, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Infusion Pumps; Irinotecan; Leucovorin; Male; Neoplasms; Neutropenia; Pharmacogenetics; Promoter Regions, Genetic; Thymidylate Synthase; Treatment Outcome	2005
Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 50, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome	2005
A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:3 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Caco-2 Cells; Camptothecin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Enzyme Induction; Female; Flavonoids; Glucuronates; Glucuronosyltransferase; Humans; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pilot Projects	2006
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial. Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Prodrugs; Rectal Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome	2005
A phase II study of dose-intensified weekly concomitant administration of cisplatin and irinotecan in chemonaive patients with extensive-disease small-cell lung cancer. Medical oncology (Northwood, London, England), 2005, Volume: 22, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis	2005
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Medical oncology (Northwood, London, England), 2005, Volume: 22, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Survival Analysis	2005
Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer. Cancer biology & therapy, 2005, Volume: 4, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Time Factors	2005
Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; France; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Multicenter Studies as Topic; Neoplasms; Neutropenia	2006
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. Oncology, 2005, Volume: 69, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Vomiting	2005
Same-day pegfilgrastim and chemotherapy. Cancer investigation, 2005, Volume: 23, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids; Vinblastine; Vinorelbine	2005
A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases. American journal of clinical oncology, 2005, Volume: 28, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p27; Disease-Free Survival; DNA, Neoplasm; Female; Fluorouracil; Gastrointestinal Diseases; Hepatectomy; Humans; Irinotecan; Life Tables; Liver Neoplasms; Male; Microsatellite Repeats; Middle Aged; Neoplasm Proteins; Neutropenia; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53	2005
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin. American journal of clinical oncology, 2005, Volume: 28, Issue:6 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Dexamethasone; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome	2005
Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). American journal of clinical oncology, 2005, Volume: 28, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Italy; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neutropenia; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Treatment Outcome	2005
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Leukocytes, Mononuclear; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oligonucleotides, Antisense; Thionucleotides	2006
Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer, 2006, Feb-01, Volume: 106, Issue:3 Topics: Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Disease Progression; Drug Administration Schedule; Female; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Neutropenia; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome	2006
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer, 2006, Mar-01, Volume: 106, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon-Nitrogen Ligases; Carcinoma; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Predictive Value of Tests; Promoter Regions, Genetic; Quinazolines; Thiophenes; Thymidylate Synthase; Vomiting	2006
Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. American journal of clinical oncology, 2006, Volume: 29, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome	2006
A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:1 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Patient Compliance; Quality of Life; Survival Analysis; Taxoids	2007
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jun-15, Volume: 12, Issue:12 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Liver Diseases; Liver Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Patient Selection	2006
[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1 Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Remission Induction; Tegafur	2006
Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-20, Volume: 24, Issue:33 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease-Free Survival; Etoposide; Female; Fever; Humans; Infections; Irinotecan; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy Dosage; Radiotherapy, Adjuvant; Severity of Illness Index; Survival Analysis; Treatment Outcome	2006
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. Investigational new drugs, 2007, Volume: 25, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Carboxylesterase; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome	2007
[Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:13 Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate	2006
Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer. Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome	2007
[Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:10 Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Survival Rate	2006
[Multicenter phase II study of modified FOLFIRI regimen in the advanced colorectal cancer patient refractory to fluoropyrimidine and oxaliplatin]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Pyrimidines; Rectal Neoplasms; Remission Induction; Treatment Failure	2006
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer. Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:1 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Survival Analysis; Thrombocytopenia; Treatment Outcome	2007
Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer, 2007, Jul-01, Volume: 110, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Female; Gene Frequency; Genotype; Haplotypes; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Membrane Transport Proteins; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neutropenia; Polymorphism, Genetic; Treatment Outcome	2007
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-01, Volume: 25, Issue:19 Topics: Adult; Aged; Area Under Curve; Camptothecin; Cytochrome P-450 CYP3A; Drug Interactions; Female; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Smoking; Treatment Failure	2007
Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. British journal of cancer, 2007, Sep-03, Volume: 97, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease Progression; Docetaxel; Esophagogastric Junction; Female; Fever; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting	2007
[10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer]. Zhonghua yi xue za zhi, 2007, Jun-05, Volume: 87, Issue:21 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Leucovorin; Male; Middle Aged; Neutropenia; Treatment Outcome	2007
Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:1 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Salvage Therapy; Topoisomerase I Inhibitors; Treatment Outcome	2008
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. Oncology, 2006, Volume: 71, Issue:5-6 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Digestive System Surgical Procedures; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Neutropenia; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Thrombocytopenia; Treatment Outcome	2006
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Palliative Care; Survival Analysis	2008
Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2008, Volume: 61, Issue:2 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia	2008
Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer. Oncology, 2007, Volume: 73, Issue:1-2 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Treatment Outcome	2007
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease Progression; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Polymorphism, Single Nucleotide; Stomach Neoplasms; Survival Analysis; Taxoids; Xeroderma Pigmentosum Group D Protein	2008
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Recombinant Proteins; Salivary Gland Neoplasms; Stomach Neoplasms; Topotecan	1994
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Thrombocytopenia; Topotecan; United States	1995
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topotecan	1995
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer research, 1994, Aug-15, Volume: 54, Issue:16 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia	1994
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer research, 1994, Jan-15, Volume: 54, Issue:2 Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Feasibility Studies; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Muscle Cramp; Neoplasms; Neutropenia; Thrombocytopenia; Vomiting	1994
[An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:1 Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neutropenia	1994
Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome	1996
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Lung Neoplasms; Neutropenia; Paclitaxel; Sepsis; Topotecan	1996
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials]. Bulletin du cancer, 1996, Volume: 83, Issue:1 Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors	1996
Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Salvage Therapy; Survival Rate; Topotecan; United States	1996
[Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer]. Nihon Sanka Fujinka Gakkai zasshi, 1996, Volume: 48, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms	1996
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Topotecan; Vomiting	1997
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fever; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction	1997
Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasm Staging; Neutropenia; Stomach Neoplasms; Thrombocytopenia	1997
A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent. American journal of clinical oncology, 1997, Volume: 20, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Quality of Life; Remission Induction; Survival Analysis; Topotecan	1997
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. British journal of cancer, 1997, Volume: 76, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Camptothecin; Fatigue; Female; Humans; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Stomatitis; Thrombocytopenia; Topoisomerase I Inhibitors; Treatment Outcome; Vomiting	1997
9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. Cancer, 1997, Nov-01, Volume: 80, Issue:9 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Thrombocytopenia; Treatment Outcome	1997
A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix. Cancer, 1998, Jan-15, Volume: 82, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Patient Satisfaction; Pilot Projects; Platinum Compounds; Remission Induction; Safety; Uterine Cervical Neoplasms; Vomiting	1998
A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anti-cancer drugs, 1998, Volume: 9, Issue:1 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors	1998
Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia	1998
A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia	1995
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer, 1999, Feb-15, Volume: 85, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoembryonic Antigen; Colorectal Neoplasms; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Vomiting	1999
Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:10 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms	1999
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Colloids; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Carriers; Female; Hematopoiesis; Humans; Infusions, Intravenous; Lactones; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia	1999
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:7 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Least-Squares Analysis; Likelihood Functions; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacokinetics; Thrombocytopenia	1999
Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Least-Squares Analysis; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Topoisomerase I Inhibitors	2000
[Neoadjuvant chemotherapy with cisplatin and CPT-11 for advanced cervical cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Uterine Cervical Neoplasms	2000
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Complex and Mixed; Neoplasms, Connective and Soft Tissue; Neoplasms, Glandular and Epithelial; Neutropenia; Time Factors	2000
Colorectal cancer: dilemmas regarding patient selection and toxicity prediction. Journal of chemotherapy (Florence, Italy), 2000, Volume: 12, Issue:3 Topics: Adult; Antineoplastic Agents, Phytogenic; Blood Proteins; Camptothecin; Colorectal Neoplasms; Creatinine; Diarrhea; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Patient Selection; Risk Factors; Urea	2000
Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study. Anti-cancer drugs, 2000, Volume: 11, Issue:4 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Feasibility Studies; Female; Humans; Irinotecan; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pleural Neoplasms; Survival Rate; Taxoids; Treatment Outcome	2000
Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Microtubules; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome	2000
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. British journal of cancer, 2000, Volume: 83, Issue:4 Topics: Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Metastasis; Neutropenia; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Factors; Thiorphan	2000
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia; Vomiting	2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Mouth Mucosa; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Quality of Life; Stomatitis; Survival Analysis	2000
Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-01, Volume: 18, Issue:23 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Vomiting	2000
A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy. Lung cancer (Amsterdam, Netherlands), 2000, Volume: 30, Issue:3 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fever; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Salvage Therapy; Taxoids	2000
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11 Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Infections; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Sensation Disorders; Treatment Outcome	2000
A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer, 2001, Jan-01, Volume: 91, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Diarrhea; Fatigue; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Prognosis; Treatment Outcome; Vomiting	2001
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Feb-15, Volume: 19, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel	2001
Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia	2001
Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome	2001
Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma. Investigational new drugs, 2001, Volume: 19, Issue:4 Topics: Adult; Antineoplastic Agents; Camptothecin; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neutropenia; Skin Neoplasms; Time Factors; Treatment Outcome	2001
Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:10 Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting	2001
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Fatigue; Female; Genotype; Homocysteine; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasms; Neutropenia; Oxidoreductases Acting on CH-NH Group Donors; Quinazolines; Thiophenes	2001
Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:9 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Oxaliplatin	2001
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12 Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors	2001
Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer. Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Treatment Outcome	2001
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Stomach Neoplasms; Survival Rate; Treatment Outcome	2001
Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Neutropenia; Stomach Neoplasms; Survival Rate; Thrombocytopenia	2001
CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer, 2002, Feb-01, Volume: 94, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Stomach Neoplasms; Treatment Outcome	2002
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-01, Volume: 20, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Thrombocytopenia	2002
Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. Anti-cancer drugs, 2002, Volume: 13, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neutropenia; Skin Neoplasms; Treatment Outcome; Uveal Neoplasms	2002
Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology, 2002, Volume: 56, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Salvage Therapy; Supratentorial Neoplasms; Thrombocytopenia	2002
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. Cancer, 2002, Apr-15, Volume: 94, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Pilot Projects	2002
Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-01, Volume: 20, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Patient Compliance; Quality of Life; Survival Analysis	2002
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jul-01, Volume: 20, Issue:13 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Deoxycytidine; Drug Administration Schedule; Esophagitis; Evaluation Studies as Topic; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leukemia; Lymphoma; Male; Middle Aged; Nausea; Neutropenia; Recurrence; Stomatitis; Treatment Outcome; Vomiting	2002
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Topotecan	1992

Other Studies

114 other study(ies) available for camptothecin and Neutropenia

Article	Year
Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:3 Topics: Adult; Antibodies, Monoclonal, Humanized; Camptothecin; Female; Genotype; Glucuronosyltransferase; Granulocyte Colony-Stimulating Factor; Humans; Immunoconjugates; Neutropenia; Triple Negative Breast Neoplasms; Uridine Diphosphate	2022
Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma. Cancer medicine, 2022, Volume: 11, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Etoposide; Humans; Irinotecan; Neoplasm Recurrence, Local; Neuroblastoma; Neutropenia; Retrospective Studies	2022
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. Current medical research and opinion, 2022, Volume: 38, Issue:8 Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; Camptothecin; Diarrhea; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Nausea; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Thrombocytopenia; Vomiting	2022
Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies. BMC cancer, 2022, Mar-31, Volume: 22, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Humans; Irinotecan; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma, Ewing; Temozolomide	2022
Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study. Oncology, 2022, Volume: 100, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Retrospective Studies	2022
Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study. International journal of clinical oncology, 2022, Volume: 27, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Diseases, Metabolic; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neutropenia; Organoplatinum Compounds; Retrospective Studies	2022
Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation. Toxicology mechanisms and methods, 2023, Volume: 33, Issue:3 Topics: Camptothecin; Diarrhea; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia	2023
[Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2022, Sep-23, Volume: 44, Issue:9 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Breast Neoplasms; Camptothecin; Consensus; Cytotoxins; Female; Humans; Immunoconjugates; Neutropenia; Receptor, ErbB-2; Trastuzumab; Triple Negative Breast Neoplasms; Ventricular Function, Left	2022
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. Cancer medicine, 2023, Volume: 12, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neutropenia; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Rectal Neoplasms	2023
The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan. ESMO open, 2023, Volume: 8, Issue:1 Topics: Camptothecin; Genotype; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic	2023
Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy. Cancer medicine, 2021, Volume: 10, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Hypertension; Japan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Prognosis; Ramucirumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Survival Rate; Vascular Endothelial Growth Factor A	2021
Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. European journal of cancer (Oxford, England : 1990), 2017, Volume: 76 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy-Induced Febrile Neutropenia; Dose-Response Relationship, Drug; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2017
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Acta oncologica (Stockholm, Sweden), 2017, Volume: 56, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Radiation Injuries; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Thrombocytopenia	2017
Interstitial lung disease following FOLFOX + FOLFIRI and bevacizumab therapy associated with leucovorin: A case report. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Lung Diseases, Interstitial; Male; Neutropenia; Organoplatinum Compounds; Tomography, X-Ray Computed	2018
UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients. Clinical laboratory, 2017, Sep-01, Volume: 63, Issue:9 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Neutropenia; Polymorphism, Genetic	2017
Carvacryl acetate, a novel semisynthetic monoterpene ester, binds to the TRPA1 receptor and is effective in attenuating irinotecan-induced intestinal mucositis in mice. The Journal of pharmacy and pharmacology, 2017, Volume: 69, Issue:12 Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Bacteremia; Camptothecin; Cytokines; Female; Intestinal Mucosa; Irinotecan; Jejunum; Mice; Molecular Docking Simulation; Monoterpenes; Mucositis; Neutropenia; TRPA1 Cation Channel	2017
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status. Oncology, 2018, Volume: 94, Issue:4 Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Disease-Free Survival; Etoposide; Female; Health Status; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Thrombocytopenia	2018
Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019, Volume: 27, Issue:3 Topics: Adult; Aged; Antacids; Antineoplastic Agents, Phytogenic; Buffers; Camptothecin; Cholagogues and Choleretics; Diarrhea; Female; Humans; Intestines; Irinotecan; Magnesium Oxide; Male; Middle Aged; Neutropenia; Retrospective Studies; Sodium Bicarbonate; Topoisomerase I Inhibitors; Ursodeoxycholic Acid; Uterine Cervical Neoplasms; Uterine Neoplasms	2019
Cost-effectiveness analysis of UGT1A16/28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients. Pharmacogenomics, 2019, Volume: 20, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplasms; Cost-Benefit Analysis; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Genotyping Techniques; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Neutropenia	2019
Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. Journal of pharmacological sciences, 2019, Volume: 140, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Forecasting; Glucuronates; Humans; Irinotecan; Leucovorin; Leukopenia; Machine Learning; Male; Middle Aged; Models, Biological; Neutropenia; Oxaliplatin; Topoisomerase I Inhibitors	2019
Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration. International journal of clinical oncology, 2014, Volume: 19, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Colorectal Neoplasms; Female; Glucuronates; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic	2014
UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Retrospective Studies	2013
Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms. World journal of gastroenterology, 2013, Jun-28, Volume: 19, Issue:24 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Fluorouracil; Glucuronosyltransferase; Heterozygote; Humans; Irinotecan; Leucovorin; Male; Neutropenia; Polymorphism, Genetic; Severity of Illness Index; Treatment Outcome	2013
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience. Anti-cancer drugs, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Carcinoma; Cohort Studies; Drug Monitoring; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Secondary Prevention; Severity of Illness Index; Survival Analysis	2013
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas, 2013, Volume: 42, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Female; Filgrastim; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Treatment Outcome	2013
5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. Chemotherapy, 2013, Volume: 59, Issue:4 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Young Adult	2013
Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients. World journal of gastroenterology, 2014, Feb-14, Volume: 20, Issue:6 Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Databases, Factual; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Thrombocytopenia; Treatment Outcome	2014
[Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2014, Volume: 36, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Esophagogastric Junction; Fatigue; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Pyrimidines; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab	2014
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma. Archives of gynecology and obstetrics, 2014, Volume: 290, Issue:5 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy; Treatment Outcome	2014
Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Young Adult	2014
Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer. Japanese journal of clinical oncology, 2014, Volume: 44, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Records; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Severity of Illness Index; Small Cell Lung Carcinoma; Treatment Outcome; Vomiting	2014
The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer. The Annals of pharmacotherapy, 2014, Volume: 48, Issue:12 Topics: Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Colonic Neoplasms; Female; Glucuronosyltransferase; Humans; Irinotecan; Liver Neoplasms; Microspheres; Mutation; Neutropenia; Polymorphism, Genetic	2014
Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer: A Pilot Study. American journal of clinical oncology, 2017, Volume: 40, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mutation; Neutropenia; Organoplatinum Compounds; Pilot Projects; Proto-Oncogene Proteins p21(ras); Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Salvage Therapy; Survival Rate	2017
A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients. The pharmacogenomics journal, 2015, Volume: 15, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Canada; Colorectal Neoplasms; Female; Genetic Testing; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide	2015
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. The pharmacogenomics journal, 2016, Volume: 16, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cohort Studies; Female; Genetic Markers; Genotype; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasms; Neutropenia	2016
[Association of UGT1A1 (28, 60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Prospective Studies; Retrospective Studies; Small Cell Lung Carcinoma	2015
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients. British journal of cancer, 2015, May-12, Volume: 112, Issue:10 Topics: Aged; Alleles; Asian People; Bilirubin; Camptothecin; Colorectal Neoplasms; Female; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Neutrophils; Nomograms; Prospective Studies	2015
Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules. The Journal of pharmacology and experimental therapeutics, 2015, Volume: 354, Issue:1 Topics: Antineoplastic Agents; Bone Marrow Cells; Camptothecin; Cell Cycle; Cell Proliferation; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Humans; Models, Biological; Neoplasms; Neutropenia; Neutrophils; Stem Cells	2015
[Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Retrospective Studies	2015
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. American journal of clinical oncology, 2016, Volume: 39, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome	2016
Relationship between UGT1A16/28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. Drug design, development and therapy, 2015, Volume: 9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biliary Tract Neoplasms; Camptothecin; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Polymorphism, Genetic; Retrospective Studies; Severity of Illness Index; Young Adult	2015
ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenetics and genomics, 2015, Volume: 25, Issue:12 Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Genetic Markers; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies	2015
UDP-glucuronosyltransferase 1A16 and 28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. International journal of clinical oncology, 2016, Volume: 21, Issue:4 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Body Fluids; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Glucuronosyltransferase; Heterozygote; Homozygote; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Prospective Studies; Risk Factors	2016
Correlation of UGT1A1()28 and ()6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. Drug metabolism and pharmacokinetics, 2016, Volume: 31, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Asian People; Camptothecin; Colorectal Neoplasms; Female; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Risk; Thailand	2016
Effects of UGT1A16, UGT1A128, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients. International journal of clinical pharmacology and therapeutics, 2016, Volume: 54, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Camptothecin; Diarrhea; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic	2016
Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. Annals of surgical oncology, 2016, Volume: 23, Issue:12 Topics: Administration, Intravenous; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Camptothecin; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Operative Time; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Postoperative Complications; Sarcopenia	2016
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. Oncology, 2016, Volume: 91, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Retreatment; Stomach Neoplasms; Survival Rate; Vomiting; White People	2016
Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genetics in medicine : official journal of the American College of Medical Genetics, 2009, Volume: 11, Issue:1 Topics: Camptothecin; Colorectal Neoplasms; Genetic Predisposition to Disease; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Models, Biological; Neoplasm Metastasis; Neutropenia	2009
Irinogenetics: how many stars are there in the sky? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-01, Volume: 27, Issue:16 Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Genetic Predisposition to Disease; Glucuronosyltransferase; Hepatocyte Nuclear Factor 1-alpha; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neutropenia; Organic Anion Transporters; Patient Selection; Phenotype; Polymorphism, Genetic; Risk Assessment; Risk Factors; Treatment Outcome	2009
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-01, Volume: 27, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Genetic Predisposition to Disease; Glucuronides; Glucuronosyltransferase; Hepatocyte Nuclear Factor 1-alpha; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Multivariate Analysis; Neutropenia; Organic Anion Transporters; Patient Selection; Phenotype; Polymorphism, Genetic; Risk Assessment; Risk Factors; Treatment Outcome	2009
UGT1A16 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. International journal of clinical oncology, 2009, Volume: 14, Issue:2* Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasms; Neutropenia; Organic Anion Transporters; Polymorphism, Genetic	2009
Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer, 2009, Sep-01, Volume: 115, Issue:17 Topics: Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Decision Trees; Genetic Testing; Genetic Variation; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Neoplasm Metastasis; Neutropenia; Quality of Life	2009
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. Pharmacogenomics, 2009, Volume: 10, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Haplotypes; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic; Risk Factors	2009
Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1. Archives of disease in childhood, 2009, Volume: 94, Issue:12 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Child; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Nasopharyngeal Neoplasms; Neutropenia; Organic Anion Transporters; Polymorphism, Single Nucleotide; Rhabdomyosarcoma, Alveolar	2009
The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fever; Fluorouracil; Follow-Up Studies; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Retrospective Studies; Stomach Neoplasms; Taxoids; Young Adult	2010
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:2 Topics: Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neutropenia; Odds Ratio; Retrospective Studies; Survival Analysis; Treatment Outcome	2010
Chemotherapy: Optimizing irinotecan regimens for colorectal cancer. Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10 Topics: Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Gene Frequency; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Quality of Life; Survival Analysis; Time Factors; Treatment Outcome	2009
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC? Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Diarrhea; Drug Therapy; Drug Therapy, Combination; Enzyme Inhibitors; Ethnicity; Etoposide; Female; Follow-Up Studies; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neutropenia; Polymorphism, Genetic; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Therapeutic Equivalency; Time Factors; Treatment Outcome	2009
[Efficacy of cetuximab combined with chemotherapy on advanced colorectal cancer: a report of 53 cases]. Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Combined Modality Therapy; Diarrhea; Exanthema; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Rectal Neoplasms; Remission Induction; Retrospective Studies	2009
Indispensability of UGT1A16 genotyping in Japanese cancer patients treated with irinotecan. International journal of clinical oncology, 2010, Volume: 15, Issue:2* Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Japan; Neoplasms; Neutropenia; Phenotype; Polymorphism, Genetic; Risk Assessment; Risk Factors; Severity of Illness Index	2010
[Utility of CPT-11 as salvage chemotherapy for progressive or recurrent breast cancer patients with multiple drug resistance]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:6 Topics: Adult; Aged; Breast Neoplasms; Camptothecin; Diarrhea; Disease Progression; Drug Resistance, Multiple; Humans; Irinotecan; Middle Aged; Neutropenia; Recurrence; Salvage Therapy	2010
[Hematological toxicity of some combined chemotherapy schemes involving aranoza]. Eksperimental'naia i klinicheskaia farmakologiia, 2010, Volume: 73, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Glycosides; Hematologic Tests; Irinotecan; Lymphopenia; Male; Methylnitrosourea; Mice; Mice, Inbred BALB C; Neutropenia; Topotecan	2010
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. British journal of cancer, 2010, Jul-27, Volume: 103, Issue:3 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Fluorouracil; Glucuronosyltransferase; Health Surveys; Humans; Irinotecan; Mitomycin; Neutropenia; Organoplatinum Compounds; Pyridines; Risk Factors; State Medicine; United Kingdom	2010
Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia. The oncologist, 2010, Volume: 15, Issue:10 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Fever; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Irinotecan; Male; Mannose-Binding Lectin; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic	2010
Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancer. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagitis; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy; Survival Rate; Treatment Outcome	2011
[Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:10 Topics: Acneiform Eruptions; Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Diarrhea; Disease-Free Survival; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; ras Proteins; Rectal Neoplasms; Remission Induction; Survival Rate	2010
Long-term survival in a patient with small-cell lung cancer undergoing hemodialysis who received multiple courses of chemotherapy. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Carcinoma, Small Cell; Female; Fever; Humans; Irinotecan; Kidney Failure, Chronic; Lung Neoplasms; Neutropenia; Renal Dialysis; Treatment Outcome	2011
Clinical implications of UGT1A128 genotype testing in colorectal cancer patients. Cancer, 2011, Jul-15, Volume: 117, Issue:14* Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neutropenia; Polymorphism, Genetic	2011
Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Diarrhea; Feasibility Studies; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Retrospective Studies; Thrombocytopenia; Treatment Outcome	2011
Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma. International journal of clinical oncology, 2011, Volume: 16, Issue:5 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans; Japan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Retrospective Studies	2011
Cost-effectiveness of UGT1A128 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2010, Volume: 13, Issue:4* Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Analysis; Decision Trees; Fluorouracil; Genetic Testing; Genotype; Glucuronosyltransferase; Granulocyte Colony-Stimulating Factor; Humans; Leucovorin; Models, Economic; Neutropenia; Polymorphism, Genetic; Severity of Illness Index	2010
Pharmacogenetic risk for adverse reactions to irinotecan in the major ethnic populations of Singapore: regulatory evaluation by the health sciences authority. Drug safety, 2011, Dec-01, Volume: 34, Issue:12 Topics: Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Ethnicity; Genetic Predisposition to Disease; Genetic Variation; Genotype; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Risk Factors; Singapore	2011
[Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2012, Volume: 132, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic; Retrospective Studies	2012
[Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms]. Zhonghua fu chan ke za zhi, 2011, Volume: 46, Issue:12 Topics: Adult; Alleles; Amplified Fragment Length Polymorphism Analysis; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Uterine Cervical Neoplasms	2011
Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer. International journal of clinical oncology, 2013, Volume: 18, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasms; Neutropenia; Polypharmacy; Retrospective Studies	2013
A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer. The pharmacogenomics journal, 2013, Volume: 13, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Genome-Wide Association Study; Genotype; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Prospective Studies	2013
Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Turkey	2012
The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens. Journal of chemotherapy (Florence, Italy), 2012, Volume: 24, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neutropenia; Platinum Compounds; Remission Induction; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Young Adult	2012
Concomitant occurrence of pulmonary invasive aspergillosis and Pneumocystis pneumonia during FOLFIRINOX chemotherapy for pancreatic carcinoma. Pancreas, 2013, Volume: 42, Issue:1 Topics: Adenocarcinoma; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillus fumigatus; Camptothecin; Fluorouracil; Humans; Invasive Pulmonary Aspergillosis; Irinotecan; Male; Middle Aged; Neutropenia; Opportunistic Infections; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pneumocystis carinii; Pneumonia, Pneumocystis; Tomography, X-Ray Computed; Treatment Outcome	2013
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. The Tohoku journal of experimental medicine, 2013, Volume: 229, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacogenetics; Polymorphism, Genetic; Stomach Neoplasms	2013
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen. British journal of cancer, 2002, Oct-07, Volume: 87, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Esophageal Neoplasms; Female; Gastrointestinal Diseases; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Treatment Outcome	2002
Irinotecan pharmacogenetics: is it time to intervene? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-15, Volume: 22, Issue:8 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Enzyme Inhibitors; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Risk; Topoisomerase I Inhibitors	2004
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-15, Volume: 22, Issue:8 Topics: Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Female; Genetic Variation; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Neutropenia; Prospective Studies; Risk; Topoisomerase I Inhibitors	2004
A preliminary study of preoperative chemotherapy combining irinotecan and cisplatin in patients with gastric cancer with unresectable para-aortic lymph node metastases. Japanese journal of clinical oncology, 2004, Volume: 34, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Female; Gastrectomy; Humans; Irinotecan; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Preoperative Care; Stomach Neoplasms	2004
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy. Journal of surgical oncology, 2004, Aug-01, Volume: 87, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Leukopenia; Liver; Liver Neoplasms; Male; Middle Aged; Neutropenia; Retrospective Studies	2004
Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-20, Volume: 23, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Humans; Irinotecan; Monitoring, Physiologic; Neutropenia; Reproducibility of Results	2005
[Induction of CPT-11 in a patient on hemodialysis with metastatic rectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Kidney Failure, Chronic; Leukopenia; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Rectal Neoplasms; Renal Dialysis	2005
Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism. Clinical colorectal cancer, 2005, Volume: 5, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cecal Neoplasms; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Irinotecan; Liver; Male; Neutropenia; Pharmacogenetics; Polymorphism, Genetic	2005
A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer. Cancer biology & therapy, 2005, Volume: 4, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Lung Neoplasms; Maximum Tolerated Dose; Neutropenia; Paclitaxel; Platinum; Survival Rate; Time Factors	2005
Risk assessment of human myelotoxicity of anticancer drugs: a predictive model and the in vitro colony forming unit granulocyte/macrophage (CFU-GM) assay. Die Pharmazie, 2006, Volume: 61, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Bone Marrow Diseases; Camptothecin; Data Interpretation, Statistical; Dogs; Dose-Response Relationship, Drug; Humans; Mice; Neutropenia; Predictive Value of Tests; Risk Assessment; Stem Cells; Tumor Stem Cell Assay	2006
Invader UGT1A1 molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan (Camptosar). The Medical letter on drugs and therapeutics, 2006, May-08, Volume: 48, Issue:1234 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics	2006
[Complete response to CPT-11 and UFT/LV combination therapy in a case with simultaneous multiple lung metastases from colon cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6 Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Leucovorin; Leukopenia; Lung Neoplasms; Middle Aged; Neoplasms, Multiple Primary; Neutropenia; Remission Induction; Tegafur; Uracil; Vomiting, Anticipatory	2006
[24 hour infusion of CPT-11/oral UFT/LV]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7 Topics: Administration, Oral; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Tegafur; Uracil	2006
[A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:9 Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survivors; Tegafur	2006
Searching for the Holy Grail of oncology. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006, Nov-15, Volume: 63, Issue:22 Topics: Antineoplastic Agents; Camptothecin; Colonic Neoplasms; Diarrhea; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Polymorphism, Single Nucleotide; Risk Assessment	2006
The role of SN-38 exposure, UGT1A128 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity. Journal of clinical pharmacology, 2007, Volume: 47, Issue:1* Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Female; Glucuronosyltransferase; Humans; Irinotecan; Lymphoma; Male; Models, Biological; Neutropenia; Polymorphism, Genetic; Regression Analysis	2007
[Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:2 Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neutropenia; Quality of Life; Rectal Neoplasms	2007
[A prevalent genetic variety of UDP-glycuronosyl transferase predicts high risk of irinotecan toxicity]. Medicina, 2007, Volume: 67, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Female; Genetic Markers; Genetic Variation; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neutropenia; Risk	2007
[Outpatient chemotherapy for lung cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:4 Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine	2007
Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan. Japanese journal of clinical oncology, 2007, Volume: 37, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Cisplatin; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Retrospective Studies	2007
Role of UGT1A16, UGT1A128 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer science, 2007, Volume: 98, Issue:9 Topics: Adult; Aged; Alleles; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; India; Irinotecan; Lung Neoplasms; Malaysia; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Polymorphism, Genetic; Singapore; Urogenital Neoplasms	2007
Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities. Clinical colorectal cancer, 2007, Volume: 6, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Predictive Value of Tests; Prodrugs; Promoter Regions, Genetic	2007
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer]. Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Rectal Neoplasms; Remission Induction; Retrospective Studies; Survival Rate; Young Adult	2007
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. Japanese journal of clinical oncology, 2007, Volume: 37, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Injections, Intravenous; Japan; Leucovorin; Male; Middle Aged; Nausea; Neutropenia; Retrospective Studies; Survival Analysis; Treatment Outcome; Vomiting	2007
Stealth and non-stealth nanocapsules containing camptothecin: in-vitro and in-vivo activity on B16-F10 melanoma. The Journal of pharmacy and pharmacology, 2007, Volume: 59, Issue:10 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Screening Assays, Antitumor; Female; Injections, Intraperitoneal; Lung Neoplasms; Melanoma, Experimental; Mice; Nanocapsules; Neutropenia; Particle Size; Polyesters; Polyethylene Glycols	2007
Re: UGT1A128 genotype and irinotecan-induced neutropenia: dose matters. Journal of the National Cancer Institute, 2008, Feb-06, Volume: 100, Issue:3* Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia	2008
Renal function as a predictor of irinotecan-induced neutropenia. Clinical pharmacology and therapeutics, 2008, Volume: 84, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Creatinine; Drug Administration Schedule; Enzyme Inhibitors; Female; Glomerular Filtration Rate; Glucuronosyltransferase; Humans; Irinotecan; Kidney; Linear Models; Male; Middle Aged; Multivariate Analysis; Neutropenia; Prospective Studies; Research Design; Retrospective Studies	2008
[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:12 Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Case-Control Studies; China; Colorectal Neoplasms; Diarrhea; Fluorouracil; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Polymorphism, Genetic; Young Adult	2007
Clinical trials referral resource. Clinical trials with 9-aminocamptothecin. Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:8 Topics: Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colonic Neoplasms; Humans; Lung Neoplasms; Lymphoma; Neutropenia	1995
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Liver; Lung; Male; Middle Aged; Neutropenia; Rectal Neoplasms; Remission Induction; Survival Analysis	1996
Continual reassessment methods in phase I trials of the combination of two drugs in oncology. Statistics in medicine, 1999, Jul-30, Volume: 18, Issue:14 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Clinical Trials, Phase I as Topic; Computer Simulation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Humans; Irinotecan; Likelihood Functions; Neoplasms; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids	1999
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:9 Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Rectal Neoplasms	1999
Moving beyond fluorouracil for colorectal cancer. The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Neutropenia	2000
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38. British journal of cancer, 2002, Jul-15, Volume: 87, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Prodrugs; Random Allocation; Tumor Cells, Cultured; Uterine Cervical Neoplasms	2002